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Gabapentinoids include drugs such as gabapentin and pregabalin, which are both 
approved by the FDA for the treatment of neuropathic pain, as well as other conditions. 
Rising prescribing trends and fatalities due to concurrent opioid overdose have created 
public health concerns regarding gabapentinoid misuse and abuse in the United States 
(US). Gabapentin prescriptions in the US increased from approximately 39 million (2012) 
to 67 million (2018) and pregabalin sales more than doubled from $2 billion (2012) to $4.4 
billion (2016). This study aimed to assess the prevalence of and factors associated with 
gabapentinoid use and misuse. 
This was a retrospective database study using Texas Medicaid prescription and 
medical claims from 1/1/12-8/30/16. Subjects were included if they: were between 18–63 
years at index date, had at least one gabapentinoid prescription, and were continuously 
enrolled for 6 months pre-index and 12 months post-index. The dependent variable in this 
study was gabapentinoid misuse while age, gender, concurrent opioid use, neuropathic pain 
diagnoses and gabapentinoid type were independent variables. 
 vii 
Of included subjects (N=39,000), 0.2% (N=81) were gabapentinoid misusers. The 
majority (76.4%) of gabapentinoid users were 41–63 years with a mean±SD age of 
48.2±10.7 years. Gabapentinoid misusers were significantly younger than gabapentinoid 
non-misusers (45.1±11.0 vs. 48.2±10.7, p=0.0084). The majority were female (68.1%), and 
a significantly higher proportion of males misused gabapentinoids compared to females 
(0.3% vs. 0.2%, p=0.0079). Over one-half (51.9%) of the study sample had neuropathic 
pain and gabapentinoid misuse was significantly higher in neuropathic pain patients 
compared to those without neuropathic pain (0.3% vs. 0.1%, p=0.0078). Over three-
quarters (77.4%) of patients were using gabapentin, however, gabapentinoid misuse was 
significantly higher among pregabalin users compared to gabapentin users (0.4% vs. 0.2%, 
p=0.0003). About one-sixth (17.3%) of gabapentinoid users had at least 90 days of 
concurrent opioid use. However, there was no significant difference in gabapentinoid 
misuse among patients with concurrent opioid use compared to patients without (0.3% vs. 
0.2%, p = 0.1440).  
The prevalence of gabapentinoid misuse was low (0.2%) among Texas Medicaid 
recipients and younger age, male gender, neuropathic pain diagnosis and pregabalin use 
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Chapter 1:  Introduction 
1.1 INTRODUCTION   
Pain is a common experience that interrupts the health and well-being of many 
people. The International Association for the Study of Pain (IASP) defines pain as “an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage or described in terms of such damage.”1 Pain can be classified based on: 1) duration 
(acute and chronic); 2) intensity (mild, moderate and severe); and 3) site of damage 
(nociceptive and neuropathic). Acute pain is self-limiting and heals within days to weeks, 
while chronic pain lasts longer than three months and can worsen over time.2, 3 Intensity 
refers to the impact or level of disruption caused by the pain experience. Mild pain is often 
treated with agents such as acetaminophen or non-steroidal anti-inflammatory drugs 
(NSAIDS) while moderate to severe pain is often treated with opioids.4, 5 Nociceptive pain 
occurs when there is damage or injury to the tissues while neuropathic pain occurs when 
there is damage to the nerves. The pain process in nociceptive pain differs from that in 
neuropathic pain, and they are managed using different types of agents. Nociceptive pain 
is generally managed with acetaminophen, NSAIDS and opioids while neuropathic pain 
management may require the use of antidepressants and anticonvulsants as well as 
opioids.2, 6, 7, 8 
Gabapentin and pregabalin are two anticonvulsants used in managing neuropathic 
pain. They are referred to as gabapentinoids and are derived from the inhibitory 
neurotransmitter γ-aminobutyric acid (GABA). They act on pain by blocking the α2δ 
subunit of voltage-dependent calcium channels to decrease excitatory neurotransmission.9 
Gabapentin (Neurontin®) was approved by the Food and Drug Administration (FDA) in 
1993 as an adjunct for epilepsy treatment in people over 12 years. This approval was 
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extended to children between 3 to 12 years in 2000, and approval for treating postherpetic 
neuralgia was granted in 2002. Pregabalin (Lyrica®) was approved for the treatment of 
diabetic peripheral neuropathy, and postherpetic neuralgia in 2004 and as adjunct treatment 
for partial onset seizures in adults in 2005. In 2007, pregabalin was approved for 
fibromyalgia.10, 11,12 Aside from their approved conditions, gabapentin and pregabalin are 
also widely used ‘off-label’ in conditions such as bipolar disorder, restless leg syndrome, 
attention deficit hyperactivity disorder and other non-neuropathic pain.10, 11 
Pregabalin is classified as a schedule V controlled substance by the Drug 
Enforcement Administration (DEA), but gabapentin is not classified as a controlled 
substance federally because it is believed to have low abuse potential.13 However, both 
pregabalin and gabapentin have come under public health scrutiny because their utilization 
rates have increased substantially within the last few years. In the United States, about 64 
million prescriptions were written for gabapentin in 2016, which represents a 49% increase 
since 2011 (Figure 1.1).14 In 2018, gabapentin prescriptions rose to 67 billion, which makes 
gabapentin the sixth most prescribed medication in the United States.15 Similarly, 
pregabalin sales increased from $2 billion in 2012 to $4.4 billion in 2016 (Figure 1.1).14 
This trend is not limited to the United States alone, as gabapentin and pregabalin 
prescriptions increased by 350% and 150% respectively over 5 years in the United 
Kingdom.16, 17 This increase in the use of gabapentinoids is not necessarily explained by a 
proportionate increase in neuropathic pain diagnosis; rather, it is believed that a response 









It has been purported that the opioid crisis started in the 1990s after physicians were 
reassured of the safety and low addiction potential of opioids by the pharmaceutical 
industry. This led to an increase in the use of opioids in pain management, and by 2011, 
238 million prescriptions were being written for opioids yearly. The ease of access and 
widespread availability of opioids led to their diversion, misuse and abuse. Consequently, 
opioid-related fatalities quadrupled between 1991 and 2010.18 Fatalities from opioid 
overdose continued to rise, with approximately 42,000 and 48,000 fatalities due to opioids 
alone in 2016 and 2017, respectively.19, 20 Various federal and state government agencies 
have responded to the opioid crisis by developing guidelines and regulations as well as 
passing legislation to restrict unwarranted opioid use.21, 22, 23 In response to the opioid crisis 
and restrictions, clinicians have employed various strategies to manage pain while reducing 
opioid consumption.14, 24 One of such strategies is the concurrent use of medications such 
as gabapentinoids with opioids.24  
The rise in gabapentinoid use is a reason for public health concern because research 
shows that the risk for respiratory depression and opioid-related death increases by 60% 
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when gabapentinoids are used in combination with opioids.13 Some studies have shown 
that people abuse gabapentinoids for the purpose of potentiating the “high” they get from 
opioids. Similarly, post-mortem studies have established the increasing presence of 
gabapentin in overdose-related fatalities. 25, 26  
While current evidence on the existence and effect of gabapentin misuse has not 
led to its reclassification as a controlled substance by the DEA, some states have taken 
regulatory and legislative action on gabapentin use. Kentucky became the first state to 
reclassify gabapentin as a schedule V controlled substance in July 2017. The 
reclassification was in response to the presence of gabapentin in 93 out of 407 (22.9%) 
cases of overdose related deaths in one county alone, as well as in one-third of all drug 
related deaths across Kentucky in 2016.13, 27, 28 West Virginia, Tennessee, Michigan, 
Virginia, North Dakota and Alabama have followed Kentucky’s lead by reclassifying 
gabapentin to schedule V medication. 29, 30, 31, 32, 33, 34 In addition to this, states such as 
Minnesota, Ohio, Wyoming, Massachusetts, Nebraska, New Jersey and Kansas have added 
gabapentin to their prescription drug monitoring programs (PDMPs).13 As of 2020, Texas 
has not reclassified gabapentin or placed it on their PDMP. 
Although evidence shows that both gabapentin and pregabalin can be misused or 
abused for their opioid potentiating effects, not much is known about the scope of their 
misuse nationally. To the author’s knowledge, only commercial databases in the United 
States have been studied to evaluate gabapentin prescribing, and to establish its prevalence 
and abuse potential.25, 35 However, these studies excluded Medicare and Medicaid patients. 
To the author’s knowledge, this study would be the first to be conducted using a state 
Medicaid population. It would also provide useful data concerning the prevalence of 
gabapentinoid misuse in Texas, which, to date, has not been reported. 
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Chapter 2:  Literature review 
2.1 CHAPTER OVERVIEW  
This chapter contains the literature review of the major concepts of this study. The 
first part gives a description on the definition, impact, cost and management of pain. The 
second part describes the use of opioids in pain management and the consequent opioid 
crisis.  Note that the second part of the literature review is described in some detail to better 
explain the reasons for the shift to gabapentinoid use. The third part discusses the use of 
gabapentinoid in pain management following the opioid crisis and restrictions on opioid 
use. The final section further elaborates on the significance of this study as described in 
Chapter 1. 
 
2.2 PAIN    
2.2.1 Definition, impact and cost of pain  
The International Association for the Study of Pain defines pain as “an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage.”1 This means pain is a multidimensional experience, 
affecting the nervous system, emotions and cognition.36  This effect on not just the 
biological framework of a person, but also on both the emotions and cognition, make pain 
a subjective experience, and as such, two people can experience and respond to the same 
type of pain in varying degrees.37, 38, 39  This varying perception and response to pain is a 
function of individual pain thresholds, genetic, environmental and psychological factors, 
and research also shows that gender and ethnicity can impact pain perception, tolerance 
and response to treatment.37, 38, 40, 41, 42 
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Despite these differences in perception and response, pain is: associated with health 
care resource utilization; a foremost cause of disability; and a significant driver of health 
care costs.42, 43 A study conducted using the 2012 National Health Interview Survey (NHIS) 
data (N = ~ 226 million), revealed that up to 126 million adults (55.8%) reported some pain 
in the three-month period prior to the survey, with 25.3 million adults (11.2%) experiencing 
chronic pain, and 23.4  million (10.3%) reporting a lot of pain. This report was also used 
to rank patients into categories of pain severity, with 14.4 million adults (6.4%) in category 
4 pain (highest level of pain) and 25.4 million adults (11.3%) in category 3.44 Another 
analysis of the prevalence of chronic pain and high-impact chronic pain from the 2016 
NHIS data, shows that about 20.4% (50 million) of adults were living with chronic pain in 
2016 and 8% (19.6 million) had high-impact chronic pain.45 High-impact chronic pain 
(HICP) is a new concept of  classifying chronic pain based on both duration and severity, 
and is used to describe a subset of the chronic pain population that is more severely 
impacted in terms of disability, and mental and cognitive impairment.46 
Consequently, health care expenditures for treating pain are estimated to range from 
$560 billion to $635 billion annually, which is greater than the yearly costs of heart disease 
($309 billion), cancer ($243 billion) and diabetes ($188 billion). This amount is also greater 
than the combined cost of cancer and heart disease ($309 billion + $243 billion), cancer 
and diabetes ($243 billion + $188 billion) or diabetes and heart disease ($309 billion + 
$188 billion).47, 48 
The impact of pain is not just observed in rising economic costs, but also in a 
person’s overall quality of life, as pain has a deleterious effect on a patient’s mood, 
capability, ability to gain employment, as well as on social and familial relationships.49 
These multifaceted effects and consequences of pain have made it one of the most 
significant crises of healthcare in America today.  
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2.2.2 Classification of pain 
There are various ways of classifying pain, but for the purpose of this review, pain 
will be classified according to its duration, intensity and site of damage.  
2.2.2.1 Duration 
Pain can be classified into acute or chronic pain, based on the time it takes for the 
underlying cause to be resolved. Acute pain is the normal physiological response to 
injurious chemical, mechanical or thermal stimulus. It occurs when pain receptors, known 
as nociceptors are activated at the site of injury or damage. It serves as a signal that an 
injury has occurred, and further attention or examination is needed. Acute pain is self-
limiting and heals within days to weeks.2, 3 
Chronic pain is defined as “pain that persists or recurs for more than three 
months.”50 The difference between acute and chronic pain is in the duration and underlying 
pain mechanism. Acute pain has a sudden onset and resolves within a few days to weeks, 
while chronic pain is persistent and exists beyond the healing period associated with acute 
pain.2 This persistence can occur as a result of changes to the nervous system that chronic 
pain causes, which prevents positive adaptation, and can lead to worsening pain as time 
passes. 51 Chronic pain is increasingly recognized as a significant public health challenge 
and has been linked to other conditions that impair quality of life, such as anxiety, 
depression, opioid dependence, limited mobility and it is also recognized as a risk factor 
for suicide. It is estimated that chronic pain alone affects about 50 million Americans, and 
higher prevalence of chronic pain is seen in women, older people and people of lower 
socioeconomic status.40, 45, 12,  51  
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2.2.2.2 Intensity 
Pain can also be classified based on its intensity as either mild, moderate or severe. 
Pain intensity is determined through various measures and scales that attempt to quantify 
pain and assess its impact on function. Using a scale of 0 to 10, mild pain can be classified 
as pain with an intensity level of 1 to 4 and is considered to have relatively low impact on 
a patient’s functioning, while moderate pain is classified as pain between 5 and 6, and 
severe pain is regarded as 7 to 10 (Figure 2.1).5  
Figure 2.1: Pain intensity numeric rating scale5, 52 
                 
   
The World Health Organization (WHO) analgesic ladder is used to make clinical 
decisions regarding pain treatment. This ladder is based on classifying pain according to 
its intensity (Figure 2.2). Mild pain is treated with agents such as acetaminophen, non-
steroidal anti-inflammatory drugs (NSAIDS) and adjuvants while moderate to severe pain 
is treated with opioids in addition to the agents for mild pain. These agents will be described 





Figure 2.2:    World Health Organization analgesic ladder53 
 
2.2.2.3 Site of damage 
Pain can be broadly categorized into nociceptive or neuropathic based on the site 
of damage. Pain resulting from damage to the tissues is referred to as nociceptive pain, 
while neuropathic pain results from damage to the nervous system.  
Nociceptive pain refers to pain that occurs as a result of damage or injury to the 
tissues.6 The term nociception describes the processes involved in pain, starting from the 
stimulus or damage, the transduction of such stimulus to impulses and the transmission of 
impulses to the spinal cord and brain, which leads to a conscious awareness of pain.2,19,20 
Nociceptive pain serves as a protection, by creating awareness of and need to care for an 
injury or damage, so that healing can occur.6, 54 Subtypes of nociceptive pain include 
visceral pain (pain in organs and smooth muscles) and somatic pain (cutaneous, myofascial 
and joint pain).2 
Neuropathic pain occurs when there is a sensory, motor or autonomic damage to  
or dysfunction in the nervous system. Unlike nociceptive pain, it is independent of a 
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stimulus and does not have a protective function.7, 25 It is commonly described as a burning, 
shooting, stabbing, tingling or prickling feeling.55 Its severity surpasses other types of pain, 
and conventional pain treatment may not be effective; hence, treatment for neuropathic 
pain usually includes antidepressants, anticonvulsants and opioids.56,8 Subtypes of 
neuropathic pain include postherpetic neuralgia, diabetic neuropathic pain, HIV-related 
neuropathic pain, neuropathic lower back pain, cancer-related neuropathic pain, complex 
regional pain syndrome and postoperative neuropathic pain.8 
 
2.2.3 Pain (nociception) processes  
The pain process refers to pathways through which injurious stimuli are recognized. 
The following four pathways are involved in the detection of pain: transduction, 
transmission, perception and modulation (Figure 2.3).54 
 




Transduction occurs when receptors, called nociceptors convert an external pain 
stimulus into nerve impulses.58 When tissue injury or damage occurs, various types of 
sensitizing chemicals and impulses are released by cells to excite nerve endings and start 
the process of wound healing. Nociceptors receive these chemical, mechanical and thermal 
impulses, and convert them to electrical signals which can then be transmitted to the spinal 
cord. Local anesthetics and antiepileptics, are useful at this level of pain mechanism, 
because they prevent those electrical signals from being formed and/or transmitted.6, 54 
2.2.3.2 Transmission 
During transmission, the electrical signals created through transduction are relayed 
along the peripheral nerve. Two peripheral nerve fibers are involved in this process, the A-
deltas and the C-fibers. The A-delta fibers are subdivided into Type I and Type II 
nociceptors. Type I have a strong response to chemical and mechanical stimuli, but can 
also respond to high thermal stimuli, while the Type II respond primarily to thermal 
stimuli.54 The A-delta fibers transmit these chemical, mechanical or thermal signals 
rapidly, and are the cause of localized, sharp, stabbing pain that is felt initially after an 
injury. C-fibers generally respond to all types of stimuli (i.e., chemical, mechanical and 
thermal), however there is a subgroup that respond selectively to either thermal or 
mechanical stimuli. C-fibers transmit pain signals slower than A-delta fibers, and are 
responsible for generalized, dull, throbbing pain that exists after injury occurs.6, 54 
2.2.3.3 Perception 
Perception refers to the process that occurs in the somatosensory cortex to make 
pain recognizable by a conscious person. At this stage, the limbic system mediates a 
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person’s affective-emotional response to pain and determines how a person perceives their 
pain.6  
2.2.3.4 Modulation 
Modulation refers to the ability of the brain to increase or decrease pain impulses. 
In modulation, the response to pain is not directly proportional to the stimulus because pain 
includes both sensory and affective elements.2 The modulation of pain is a function of 
somatosensory inputs, emotional and motivational components. This means that the ability 
to “block out” or “feel” pain can be influenced by mechanisms other than those from the 
injury, as well as a person’s attention to or distraction from the pain.6, 54 The production of 
excitatory or inhibitory neurotransmitters by the body can upregulate or downregulate pain 
impulses. Descending pathways that extend from the brain to the dorsal horn in the spinal 
cord, can also exaggerate or weaken the impulses to the brain.19, 20  Production and release 
of excitatory neurotransmitters, such as glutamate, substance P, and calcitonin gene-related 
peptide (CGRP) can increase sensitivity to pain impulses, while the release of inhibitory 
neurotransmitters like γ-aminobutyric acid (GABA), serotonin, endorphins and 
norepinephrine can decrease sensitivity to pain.19, 20, 4 
 
2.2.4 Management and treatment of pain 
The focus of this research is to evaluate the use and misuse of gabapentinoids in 
pain management; however, other methods of pain management, particularly opioids will 
be reviewed, as opioid use is a risk factor for gabapentinoid misuse.59, 60, 61 Strategies to 
address pain include both pharmacological and non-pharmacological approaches. 
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2.2.4.1 Non-pharmacological intervention 
Non-pharmacological interventions include strategies that are used alone or in 
conjunction with pharmacological therapy to ease pain. They include transcutaneous 
electrical nerve stimulation, acupuncture, massage and exercise.62, 63  
2.2.4.2 Pharmacological intervention 
Pharmacological therapy for pain can be broadly divided into three areas: non-
opioid analgesics, opioid analgesics and adjuvants such as antidepressants, anticonvulsants 
and corticosteroids.64 Non-opioid analgesics include acetaminophen and nonsteroidal anti-
inflammatory drugs (NSAIDs), which are the agents recommended in the first step of the 
WHO analgesic ladder (Figure 2.2). The ladder is a step-wise approach to managing pain, 
with non-opioids recommended as the first step for mild pain, weak opioids for moderate 
pain and strong opioids for severe pain. This step-wise approach has been used to develop 
various evidence-based guidelines for managing different types of pain. However, for 
conditions such as neuropathic pain, the use of other medications such as antidepressants 
and anticonvulsants (e.g., gabapentin and pregabalin), as well as opioids have been 
recommended.65, 66 The choice of pharmacological treatment is determined after weighing 
the benefits and risks, particularly regarding opioid therapy. 
 
 
2.3 THE USE OF OPIOIDS IN PAIN MANAGEMENT  
2.3.1 Introduction 
Opioids refer to a class of drugs that act mainly on the mu opioid receptor to 
produce analgesic effects. In addition to mu, the other target receptors are delta, kappa and 
 14 
nociception opioid receptors. Opioids include compounds such as morphine and codeine, 
which are derived directly from the opium poppy plant, as well as synthetic analogues such 
as oxycodone, hydrocodone and buprenorphine.67, 68 Opioids are widely used to treat 
moderate to severe pain, and about 58 opioid prescriptions were written for every 100 
Americans in 2017.69 Opioids are also commonly used for managing cancer pain, and pain 
due to terminal diseases, such as AIDS and degenerative diseases. Some of their benefits 
include: decreased pain, better pain management, improved physical function and 
increased quality of life.70 However, despite their usefulness in pain management, opioids 
also have a variety of complications such as sedation, constipation, nausea, vomiting, 
tolerance, dependence, respiratory depression, hyperalgesia, immunosuppression,  
hormonal changes, risk of misuse and abuse as well as fatalities due to overdose.71, 72 
Therefore, alternative analgesic options should be considered before opioid use, and when 
opioid use is inevitable, treatment should start with the lowest effective dose and titrated 
upwards if needed.72 
Opioid agonists produce potent anti-nociceptive action through binding to opioid 
receptors within the central and peripheral nervous system.73 These receptors modulate 
pain, regulate the reinforcement and reward system, regulate mood and respond to stress.74 
The type of receptor and affinity of the opioid to the receptor contributes to the extent of 
analgesia produced. Opioids act on the transmission stage of the pain process, by indirectly 
stimulating and activating descending inhibitory neurons. This increase in neuronal traffic 
leads to a decrease in the transmission of pain from the periphery to the brain.75, 76 
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2.3.2 Classification of opioids 
As shown in the WHO analgesic ladder (Figure 2.2), opioids are prescribed based 
on pain intensity and are classified into strong, intermediate and weak. Strong opioids 
include morphine, pethidine, fentanyl, methadone and oxycodone; intermediate opioids 
include buprenorphine, pentazocine and butorphanol; while weak opioids include codeine 
and tramadol (Table 2.1).77 
Opioids can also be classified as either endogenous or exogenous. Endogenous 
opioids are those created by the body, and they include, endorphins, enkephalins, 
dynorphins and endomorphins.68 Exogenous opioids can be subdivided into naturally 
occurring compounds like morphine, semi-synthetic opioids such as oxycodone, 
hydromorphone and hydrocodone, and synthetic opioids like methadone, tramadol and 
fentanyl (Table 2.1).  
A third form of classification is based on their interaction with opioid receptors into 
full agonists, partial agonists and antagonists. Full and partial agonists bind to receptors 
but produce different levels of receptor activation or response. Full agonists have high 
efficacy and produce the maximum activation possible when they bind to a receptor. Partial 
agonists on the other hand produce sub-maximal response compared to a full agonist even 
when they have similar or higher binding affinity to the receptor. Consequently, a partial 
agonist can display antagonistic effects in the presence of a full agonist by competing with 
the full agonist for receptor occupancy. This reduces the ability of the full agonist to elicit 
the maximum response it is capable of producing when used alone. Examples of full 
agonists include morphine, fentanyl and oxycodone and partial agonists include 
buprenorphine, pentazocine and butorphanol (Table 2.1).78, 79 Antagonists refer to 
medications that block the activity of opioids, by competing for opioid receptors because 
they have higher binding affinity than agonists but do not elicit receptor activation. This 
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makes them useful for addressing opioid dependence and overdose, examples include 
naloxone and naltrexone (Table 2.1).77 
 
Table 2.1: Classification of opioids68, 77 




Morphine  Strong Naturally occurring Full agonist 
Oxycodone  Strong Semi-synthetic Full agonist 
Hydrocodone  Strong Semi-synthetic Full agonist 
Hydromorphone  Strong Semi-synthetic Full agonist 
Fentanyl Strong Synthetic Full agonist 
Methadone Strong Synthetic Full agonist 
Pethidine Strong Synthetic Full agonist 
Meperidine Strong Synthetic Full agonist 
Buprenorphine Intermediate Semi-synthetic Partial agonist 
Pentazocine Intermediate Synthetic Partial agonist 
Butorphanol Intermediate Synthetic Partial agonist 
Codeine Weak Naturally occurring Full agonist 
Tramadol Weak Synthetic Partial agonist 
Naloxone - Semi-synthetic Antagonist 






Opioids are available as both immediate and extended release formulations. 
Immediate release formulations are used for both acute and chronic pain, while extended 
release formulations are used for chronic pain when immediate release opioids are no 
longer adequate.80, 81 Despite the popular use of opioids in managing chronic pain, 
controversy exists about their efficacy, as there is limited evidence on their superiority over 
non-opioids in chronic pain management.82, 83 
Opioids are used to manage various types of pain such as dental, cancer, muscle, 
joint, back, abdominal, post-traumatic and post-surgical pain.84, 85 They are also used in 
addition to adjuvant analgesics for neuropathic pain; however, their use is controversial as 
some types of neuropathic pain may be non-responsive to opioids.86 Opioids can also be 
combined with other drugs and used for non-pain treatment, for example, codeine and 
hydrocodone can be combined with other drugs to treat cough.87 
 
2.3.4 Guidelines for the use and prescription of opioids 
The Centers for Disease and Control (CDC) guidelines for management of chronic 
pain (released in 2016) have three main objectives;88  
“1. Improve communication between providers and patients about the risks and 
benefits of opioid therapy for chronic pain. 
2. Improve the safety and effectiveness of pain treatment. 
3. Reduce the risks associated with long-term opioid therapy, including opioid use 
disorder and overdose.” 
The key concepts of the guidelines include: considering non-pharmacologic or non-
opioid therapy before opioids, establishing treatment goals before initiating opioid therapy, 
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assessing patient’s risks and benefits, using immediate-release opioids at the start of opioid 
therapy instead of extended or long-acting opioids for either acute or chronic pain, using 
lowest effective dose and titrating upwards slowly avoiding an increase of ≥ 90 morphine 
milligram equivalents (MME)/day, reviewing controlled substances history, using urine 
drug testing, avoiding concurrent benzodiazepine use and providing treatment for opioid 
use disorder.44 
Various states also have specific opioid guidelines, with most of them sharing 
recommendations similar to the CDC guidelines, such as, using non-opioid therapy as first 
option for acute pain, and where opioid use is warranted, using the lowest effective dose. 
Others include avoiding the use of long-term opioids for acute pain, including appropriate 
counselling and assessment strategies when opioids are used for chronic pain, avoiding the 
concurrent use of opioids with benzodiazepines, as well as providing education on opioid 
overdose.89, 90 Most of these guidelines were established following the opioid crisis. 
 
2.3.5 The opioid crisis 
It has been purported that the opioid epidemic started in the 1990s after physicians 
were reassured of the safety and low addiction potential of opioids by the pharmaceutical 
industry. This led to an increase in the prescription and use of opioids in pain management, 
and by 2011, 238 million prescriptions were being written for opioids annually. This 
resulted in diversion and misuse of opioids, and the fatality rate from opioid overdoses 
quadrupled between 1991 and 2010.18 In 2010, over 16,000 people died from opioid 
overdoses, and within six years, the number more than doubled, with over 42,000 
Americans reportedly dying from opioid overdoses in 2016 alone.18, 19 In addition to the 
fatalities, an estimated 11.4 million people misused prescription opioids, 2 million misused 
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opioids for the first time and 2.1 million people had an opioid use disorder in 2016 alone.88, 
19 In response to the escalation of these issues, in 2017, the US Department of Health and 
Human Services declared the opioid crisis a public health emergency and released a five-
point strategy to address the crisis (see Section 2.3.6 for more details).21 
In addition to fatalities, other consequences of opioid misuse and abuse include 
neonatal abstinence syndrome, anxiety, depression, lowered motivation and productivity, 
impaired social functioning, structural changes to the brain, as well as bleeding disorders.91, 
92, 93 The opioid crisis also had a significant economic impact, as costs related to the opioid 
crisis in 2016 alone were $95.8 billion with an estimated total of over $1 trillion since 
2001.94 All of these factors have led to various responses and interventions at the federal, 
state and local levels to address the crisis. 
 
2.3.6 Restrictions and legislation to address the opioid crisis 
Some of the responses to the opioid crisis have been the creation of guidelines, 
legislation and programs to regulate and monitor opioid prescribing and use. As part of the 
federal government’s efforts to reduce opioid related deaths, the Department of Health and 
Human Services released a five-point strategy in 2017 aimed at: 1) increasing access to 
prevention, treatment and recovery services, 2) increasing the availability and access to 
opioid overdose-reversing medications, 3) strengthening the reporting and collection of 
public health data, 4) supporting research on pain and addiction, and 5) advancing research 
that can provide evidence based pain management strategies, and reduce unnecessary use 
of opioids.21 
The Drug Enforcement Agency (DEA) uses a three-part approach to combat the 
opioid crisis, which includes: 1) employing law enforcement actions against drug cartels, 
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2) using diversion control enforcement activities and 3) engagement with DEA registrants, 
pharmaceutical businesses and practitioners, as well as community-based outreach.95  
States have also responded to the crisis by enacting laws and policy-based 
interventions. State Prescription Drug Monitoring Programs (PDMPs) use electronic 
databases to track prescription and dispensing patterns for specific medications. The use of 
PDMPs has facilitated tracking of opioid prescribing and dispensing, reduced the ease of 
doctor and pharmacy shopping for opioids, as well as decreased opioid misuse and 
diversion.22, 23 In addition, about 30 states have implemented stricter opioid control 
measures, by imposing various types of legal limitations on opioid prescribing.96 There are 
also various recommendations and grants by community led partnerships and coalitions, 
aimed at supporting these federal and state government strategies.97, 98 
Pharmacological strategies used to combat opioid use disorder and fatalities include 
naloxone distribution programs and Medication-Assisted Treatment (MAT).99 Naloxone is 
an opioid antagonist that can reverse respiratory depression caused by opioid overdose. It 
does not have any euphoric effect and is not effective for non-opioid related overdoses. 
Currently, all 50 states and Washington DC have passed legislation that facilitates access 
and distribution of naloxone.100, 101, 102,103 MAT involves the use of two opioid 
agonists/partial agonist, methadone and buprenorphine, in conjunction with naltrexone to 
manage opioid withdrawal symptoms, decrease opioid cravings and block the effect of 
opioids. These medications are used in conjunction with counselling and behavioral 
therapies for a holistic approach to recovery and prevention of relapse.99, 104, 105 
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2.3.7. Impact of opioid restriction on the use of non-opioid analgesics for pain 
management  
The need to properly manage pain while addressing the challenge of opioid misuse 
and abuse have led to providers exploring other pain management strategies, such as 
concurrent use of non-opioid medications (e.g., gabapentinoids and muscle relaxants). The 
goal of this strategy is to reduce the use of and dependence on opioid therapy, by using 
alternative therapies that have relatively liberal restrictions on their use.14, 60  
Gabapentin and pregabalin are both approved by the FDA for neuropathic pain. 
However, studies show that there has been an upward trend in their prescription rate. In 
England over the last 5 years, gabapentin and pregabalin use have increased by 350% and 
150%, respectively.106 In the United States, about 64 million prescriptions were written for 
gabapentin in 2016, which represents a 49% increase since 2011. Similarly, pregabalin 
sales increased from $2 billion in 2012 to $4.4 billion in 2016.14, 16 The increase in risk of 
respiratory depression and subsequent fatalities when gabapentinoids are used alongside 
opioids, as well as the growing evidence for their misuse and abuse, have led to public 
health concerns regarding the use of gabapentinoids in pain management.107 
 
2.4 USE AND MISUSE OF GABAPENTINOIDS  
2.4.1 Introduction 
Gabapentinoids refer to a class of drugs that are derived from the inhibitory 
neurotransmitter γ-aminobutyric acid (GABA). They are also referred to as α2δ ligands, as 
they block the α2δ subunit of voltage-dependent calcium channels to decrease excitatory 
transmission. They include drugs such as pregabalin, gabapentin, as well as gabapentin 
enacarbil, which is a gabapentin prodrug.  
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Gabapentin and pregabalin were the first α2δ ligands to be synthetized for use in 
epilepsy treatment but were later found to be effective in treating other conditions.108 
Currently they are both approved by the FDA for the treatment of neuropathic pain among 
other conditions. Their efficacy in neuropathic pain is assumed to result from the reduction 
in calcium influx and subsequent inhibition of excitatory neurotransmitter release that 
occurs when they bind to the α2δ subunit of voltage-dependent calcium channels.
9 
Despite their structural similarity, pregabalin is six times more potent in its binding 
activity to the α2δ subunit than gabapentin. It is also absorbed three times faster than 
gabapentin and has greater bioavailability than gabapentin.9, 109 The bioavailability of 
gabapentin reduces from about 60% following a 900mg dose/day to 33% and 27% 
following a 3600mg and 4800mg dose/day, respectively.110 However, pregabalin maintains 
a bioavailability of about 90% irrespective of the dose.9 
Pregabalin is also considered to have a higher potential for misuse and abuse than 
gabapentin, and as such was categorized as a schedule V drug by the DEA before its release 
to the market. Gabapentin was considered to have a low risk of abuse or addictive effect 
and was not listed as a controlled substance. However, recent research indicates gabapentin 
may potentiate the euphoric effect of opioids, and increase the risk of respiratory 
depression and opioid-related mortality.60 This discovery led Kentucky, West Virginia, 
Tennessee, Michigan and Virginia to list gabapentin as a schedule V controlled 
substance.30,31, 32, 111 Other states are currently establishing legislative regulations to 
monitor gabapentin use, drafting policies or gathering data to support decision making. 60 
The maximum recommended daily dosage for pregabalin varies between 450mg 
for fibromyalgia to 600mg for diabetic neuropathy, postherpetic neuralgia and partial onset 
seizures. For gabapentin, the maximum daily dose is 1800mg for postherpetic neuralgia 
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and 3600mg for partial onset seizures. Side effects of gabapentin and pregabalin include 
fatigue, dizziness, nausea, somnolence and ataxia.112, 110 
 
2.4.2 History 
Gabapentin (Neurontin®) was approved in 1993 as an adjunct treatment for partial 
complex seizures in people over 12 years old, and this approval was extended to include 
children from age 3 to 12 in 2000. In 2002, gabapentin was approved for the treatment of 
postherpetic neuralgia.113 Generic gabapentin became available in 2004 after the first 
generic equivalent of Neurontin® was approved by the FDA in 2003.10 Pregabalin (Lyrica®) 
was approved for the treatment of diabetic peripheral neuropathy and postherpetic 
neuralgia in 2004, adjunct treatment of partial onset seizures in 2005, fibromyalgia in 2007, 
and neuropathic pain associated with spinal cord injury in 2012. In 2012, an extended 
release version was approved for diabetic neuropathy and postherpetic neuralgia.11, 12 The 
first generic pregabalin was approved by the FDA in 2019.114 In addition to these approved 
conditions, gabapentin and pregabalin are also used off label for conditions such as bipolar 
disorder, attention deficit hyperactivity disorder, restless leg syndrome, trigeminal 
neuralgia and other non-neuropathic pain.115 
 
2.4.3 Guidelines for use in neuropathic pain 
2.4.3.1 Gabapentin use in postherpetic neuralgia  
Treatment should begin as a single dose of 300mg on the first day, increased to 
600mg (300mg twice) on the second day and 900mg (300mg thrice) on the third day. This 
can be titrated upwards to a maximum of 1800mg a day (600mg three times daily) for 
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postherpetic neuralgia. However, for partial-onset seizures, the dose can be titrated to a 
maximum of 3600mg. The above recommendation is for patients with normal renal 
function, measured as creatinine clearance above 60ml/min. For patients with impaired 
renal function, the dose is calculated based on their creatinine clearance (Table 2.2).116 
Table 2.2: Gabapentin dosage based on renal function116 
Creatinine clearance (ml/min)  Total daily dose (mg/day) 
≥ 60 900 to 3600 
30 to 59 400 to 1400 
15 to 29 200 to 700 
<15 100 to 300 
 
2.4.3.2 Pregabalin use in postherpetic neuralgia  
Treatment should begin with a dose of 75mg twice daily or 50mg thrice daily 
(150mg/day). This can be increased to a dose of 300mg/day within a week. If a dose of 
300mg/day is insufficient after 2 to 4 weeks, then treatment may be titrated up to 300mg 
twice daily or 200mg thrice daily (600mg/day). In patients with impaired renal function, 
the dose administered is based on creatinine clearance (Table 2.3).112 
2.4.3.3 Pregabalin use in diabetic neuropathy  
Treatment should begin with a dose of 50mg taken thrice daily (150mg/day). This 
can be increased to the maximum recommended dose of 100mg thrice daily  (300mg/day). 
In patients with impaired renal function, the dose administered is based on creatinine 
clearance (Table 2.3).112 
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Table 2.3: Pregabalin dosage based on renal function112 
Creatinine clearance (ml/min)  Total daily dose (mg/day) 
≥ 60 150 to 600 
30 to 59 75 to 300 
15 to 29 50 to 150 
<15 25 to 75 
 
2.4.5 Gabapentinoid misuse  
2.4.5.1 Introduction  
Drug misuse can be defined as the use of a medication for a purpose that is 
inconsistent with medical or legal guidelines. Drug misuse can refer to using another 
person’s medication, administering the medication through an unprescribed route, or using 
doses higher than prescribed.117, 118 While there may be some overlap in defining drug 
misuse and abuse, it is important to note that drug misuse and abuse refer to two different 
ideas.117, 119 One of the reasons misuse and abuse might be incorrectly used interchangeably 
is because various health agencies and organizations define these terminologies differently, 
so a wide range of operational definitions for misuse and abuse exist.119, 120, 121 However, a 
majority of the definitions of drug misuse tend to restrict the term “misuse” to the improper 
use of prescription or over-the-counter medications, for therapeutic purposes or with 
therapeutic intent.117, 119, 122 Abuse, on the other hand is used to refer to the use of prescribed 
or illicit substances for nontherapeutic purposes or to obtain certain mind altering effects, 
such as sedative, anxiolytic or euphoric effects.117, 119, 123  
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The misuse of prescription opioids, CNS depressants and stimulants has been 
established as a public health concern in the United States. In 2017, an estimated 18 million 
people misused prescription medications at least once within the past year, and 2 million 
people misused prescription pain relievers for the first time within the past year according 
to the Substance Abuse and Mental Health Services Administration (SAMSHA).124 Also, 
over 1 million people misused prescription stimulants, about 1.5 million people misused 
tranquilizers and 271,000 people were first time sedative misusers, all within the past 
year.124 
Gabapentinoids are emerging as a drug class of public health concern as they have 
come under public health scrutiny for their rising prescribing trends and their presence in 
fatalities due to medications, specifically opioid overdose. The gabapentin prescription rate 
in the United States increased from approximately 39 million in 2012 to 64 million in 
2016.14 According to a report on medicine use and spending in the United States, 
gabapentin prescriptions rose further to 67 million in 2018 making it the sixth highest 
prescribed medication in 2018.15 This upward spike in recent years is noteworthy as 
gabapentin was approved for epilepsy and postherpetic neuralgia in 1993 and 2004, 
respectively,113 and there are no recent FDA-approved indications for gabapentin that can 
justify or explain this rise. Similarly, the sales of pregabalin more than doubled to about 
$4.4 billion in 2016, from about $2 billion in 2012.14  
Although the CDC recommends gabapentinoids as first-line agents for the 
treatment of neuropathic pain, this rise in their utilization cannot be explained by a 
concurrent increase in neuropathic pain diagnosis or newly approved indications. Thus, the 
significant increase in gabapentinoid use is presumed to be a response to the need for 
alternatives to opioids for pain management.14 
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2.4.5.2 Evidence and consequences of gabapentinoid misuse  
Several studies in Europe indicating an increase in gabapentin and pregabalin use 
led to subsequent investigation of gabapentin and pregabalin abuse in Europe and beyond. 
A study investigating pregabalin abuse using the Swedish spontaneous adverse drug 
reaction reporting system was published in 2010. The results showed there was a rapid 
increase in pregabalin use within two years (9.3 million defined daily doses used in 2009, 
compared to 4.6 million defined daily doses in 2007) and in the likelihood of pregabalin to 
be abused. They also identified 16 cases indicative of pregabalin abuse out of 198 reports 
of drug abuse or addiction.125, 126 A similar pharmacovigilance study published in 2016 
using the French pharmacovigilance database identified 8 pregabalin cases out of 521 drug 
abuse or dependence cases between January 1, 2010 and December 31, 2015.127 A study 
published in 2013 using the German Federal Institute for Drugs and Medical Devices 
identified fifty-five reports of pregabalin abuse and dependence between April 2008 and 
August 201212 Another study in Scotland, published in 2012 found that there were 
noticeable increases in gabapentin prescriptions since 2002 when it was approved for 
postherpetic neuralgia. They also found the presence of gabapentin in postmortem reports 
(48 out of 1,400 post-mortem reports included gabapentin).128  
An analysis of the European Medicines Agency’s EudraVigilance database 
between 2004 to 2015 showed that about 6.6% (7,639 out of 115,616) and 4.8% (4,301 out 
of 90,166) of reports regarding abuse, misuse or dependence were associated with 
pregabalin and gabapentin, respectively. They also discovered that 27 and 86 deaths were 
attributable to pregabalin and gabapentin, respectively, and most of these deaths occurred 
in cases with concomitant opioid use. Although this study evaluated reports over a twelve 
year span (2004-2015), about 67% percent of the pregabalin cases and 60% of the 
gabapentin cases they identified occurred within 3 years alone (2013-2015), which 
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indicates a sharp rise in those years compared to previous years.129 The rise in 
gabapentinoid abuse-related events and deaths identified in recent years in the European 
pharmacovigilance database has also been identified in the United States. Evoy et al. 
analyzed the Food and Drug Administration Adverse Events Reporting System (FAERS) 
between 2012 to 2016.59 They found that a larger percentage of the gabapentinoid abuse-
related events and deaths occurred within the two most recent years of the study (2015-
2016). Out of 10,038 gabapentin adverse events identified within 2012-2016, 5.7% (576 
out of 10,038) were events specifically related to gabapentin abuse. Of these 576 abuse-
related events, 66% (381 out of 576) occurred between 2015 and2016 alone. Also, 106 of 
these 576 abuse-related events led to fatalities, 66% (70 out of 106) of which occurred 
between 2015 and 2016. Within this time frame (2012 – 2016), 571 pregabalin adverse 
events were identified. Approximately 10% [10.2% (58 out of 571)] of these events were 
reports related to pregabalin abuse. Of these 58 abuse-related events, 60% (35 out of 58) 
occurred between 2015 and 2016. Out of the 58 abuse-related events, 24 fatalities were 
recorded, with 83% (20 out of 24) of these deaths in 2015 to 2016 alone.59 
A study by Smith et al. (N = 33) conducted in Appalachian Kentucky, United States 
was used to characterize patterns and reasons for gabapentin misuse. They found that most 
patients were initiated on gabapentin for indications such as neuralgia, insomnia, 
depression, anxiety and opioid detoxification. Also, some respondents considered 
gabapentin more effective than opioids for their pain, cheaper than opioids, as well as 
helpful for coping with withdrawal symptoms from opioids. They also found that the 
respondents used specific doses to give them the “high” they wanted, but most of them 
preferred to take them with caffeine, because caffeine “makes them better.”130 These 
findings were consistent with a larger study (N = 503) conducted by the same group, also 
in Appalachian Kentucky.131, 132 They found that about 15% of participants who reported 
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using prescription opioids for nonmedical use also used gabapentin “to get high”. Also, 
drug dealers were a major source of obtaining gabapentin (36%) while prescriptions written 
by physicians accounted for 52% of access to gabapentin within this cohort. In addition, 
gabapentin was reported to be available from drug dealers at a cost of less than $1 per 
pill.131, 132 
Evoy et al. conducted a systematic review (N = 59 studies) on gabapentinoid abuse 
and concluded that there is an increasing trend in patients taking higher than prescribed 
doses to attain euphoria. They also found that the number of people who abused 
gabapentinoid in the general population was 1.6%, but prevalence of gabapentinoid abuse 
among those abusing opioids was higher, and ranged from 3% to 68% across different 
studies.126 
Peckham et al. conducted the first large retrospective database study analyzing the 
prevalence and predictors of gabapentin abuse using the Truven Health MarketScan® 
commercial database.25 The database contains medical and pharmacy claims for about 50 
million people with commercial insurance, of which 840,000 were included in the study. 
They calculated Lorenz-1 curves to determine the proportion of consumption in the top 1% 
of users compared to the total population utilization. Gabapentin and pregabalin had 
Lorenz-1 values of 19% and 15%, respectively. This indicates the abuse potential of 
gabapentin and preagablin as they both met the standard 15% threshold value which is 
associated with high abuse potential.25, 59 They also found that about 40% of gabapentin 
users and 39% of pregabalin users had concurrent opioid use for at least 120 days.25 In a 
subsequent study, they found that 24% of patients who had both gabapentin and opioid 
prescriptions had no less than three pharmacy claims that exceeded recommended dosage 
limits, in contrast to 3% of patients on gabapentin only and 8% of patients on opioids 
only.61 
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Another retrospective database study was conducted by Pauly et al. using the IBM 
Marketscan® Commercial Claims and Encounters Database.35 The database contains 
administrative claims for about 20 to 30 million enrollees annually. The study evaluated 
the trends in gabapentin prescription from 2009 to 2016. They found that the prevalence of 
gabapentin prescribing in 2009 was 13.3 recipients per 1,000 beneficiaries. However, by 
2016, the prevalence had more than doubled to 27.1 recipients per 1,000 beneficiaries. 
They also found that gabapentin prescribing rates differed across the United States, with 
Kentucky having the highest rate of 43.9 recipients per 1000 beneficiaries and Washington 
DC. having the lowest rate of 12.7 recipients per 1000 beneficiaries.35 A post-mortem study 
in five sites within the United States (Kentucky, Maricopa county in Arizona, North 
Carolina, Northeast Tennessee and West Virginia) found that gabapentin was implicated 
in an average of 22% of overdose-related deaths. This positive association of gabapentin 
with overdose deaths varied significantly across the different locations; Northeast 
Tennessee was the lowest (4%) while Kentucky was the highest (41%).26 
Another study investigating gabapentin levels in post-mortem cases was conducted 
in West Virginia. They reviewed fatalities that occurred over 4 years (2014 to 2017) within 
the Western region of the Office of the Chief Medical Examiner in West Virginia and found 
104 cases where gabapentin was present. The chief pathologist determined that gabapentin 
played a direct role in 49 fatalities and a contributory role either by toxicity or overdose in 
11 other cases.133 
There are currently no national estimates on mortality, morbidity, or economic 
losses due to gabapentinoid misuse in the United States. The studies evaluating 
gabapentinoid misuse and abuse have described some of the clinical effects of misuse and 
abuse, as well as the increased consequences when used concomitantly with opioids.59, 126, 
129, 130, 131  Some misusers of pregabalin have described a dose related effect when 
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pregabalin is misused. At 900mg, pregabalin misusers experience some euphoria, difficulty 
walking, drunken feeling and color altered vision. At 1200mg, euphoria and drowsiness is 
established and at doses greater than 1500mg, misusers experience hallucinations, 
increased euphoria, dissociation and anxiety.134 
The concern about gabapentinoid misuse increases in patients who use opioids, as 
the risk of fatality from opioid overdose is increased. Research shows that there is a 
possible increase of up to 60% in opioid-associated deaths when doses of gabapentin 
greater than 900mg are used concurrently with opioids. This is because gabapentin misuse 
in combination with opioids can lead to a fourfold increase in the risk of respiratory 
depression.61 In December 2019, the FDA issued warnings about the possibility of severe 
breathing problems in patients using gabapentin or pregabalin.135 The agency also required 
that the labeling of gabapentinoids be updated with warnings on the risk of respiratory 
depression. In addition, the agency is requiring manufacturers to conduct clinical trials 
evaluating the abuse potential of gabapentinoids with focus on assessing their respiratory 
depressant effects.135, 136  
Gabapentinoid misuse has been identified and defined in different ways: self-report 
of participants in prospective research,130, 131 presence of gabapentinoids in toxicology 
reports26, 128, 133, 137 analysis of pharmacovigilance database12, 59, 125, 127, 129 and consistent 
overdose identified through prescription claims.61, 25, 111 Due to the nature of this study (i.e., 
secondary database analysis) and to aid comparison with similar studies,111, 59 misuse will 
be defined as three or more pharmacy claims exceeding a daily dose threshold of 3600mg 
for gabapentin and 600mg for pregabalin.  
There is evidence to show that gabapentinoid misuse and abuse is becoming a 
significant concern within the United States and beyond. The increase in drug overdose 
cases and fatalities involving gabapentinoids has attracted notable research interest. The 
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misuse and abuse potential of gabapentinoids is an emerging research area, and as such, 
there are gaps in describing the effects and consequences of gabapentinoid misuse across 
different population groups. One such gap is the absence of investigation into 
gabapentinoid misuse among Medicaid recipients.  
2.4.5.3 Factors associated with gabapentinoid misuse  
Factors contributing to increased gabapentinoid misuse include: easier access to 
gabapentinoid prescriptions, lower costs than opioids, limited prescriber knowledge 
regarding abuse potential, non-classification of gabapentin as a controlled substance, and 
prevalent use for off-label conditions.126, 60,118,131 
The risk for gabapentinoid misuse is also increased in patients with previous or 
concurrent opioid use or abuse.126,118 When gabapentinoids are used in combination with 
opioids, they may potentiate the euphoric effect of opioids, which can lead to opioid users 
seeking and using higher than prescribed doses of gabapentinoids. Some studies show that 
overdose of gabapentinoids alone may not have lethal effects but when used in addition to 
opioids and sedatives, they can lead to respiratory depression and opioid-associated 
fatality.138, 60 A case control study evaluating opioid users in Canada found that about 46% 
of gabapentin users had at least one concurrent opioid prescription, and this concomitant 
use of gabapentin and opioids increased the risk of opioid related fatality by 49%.107 
The post-mortem study conducted in Scotland found that 75% of cases (36 out of 
48) with gabapentin in their toxicology report also had morphine and/or methadone on their 
report.128 Similarly, Peckham et al. in their analysis of the Truven Health MarketScan® 
database found that only 2% of patients on gabapentin without opioids met their criteria 
for prolonged overuse, while 11% of patients on gabapentin and opioids were in the 
prolonged overuse category. They also found that predictors or risk factors for misuse 
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differed between the two groups: the gabapentin-only group having insomnia, euphoria and 
bipolar disorder as the top three predictors, while the gabapentinoid and opioid group had 
detoxification, altered mental state and addiction as their top three risk factors.111 
Another toxicology study examining the prevalence of gabapentin in impaired 
driving cases, found only about 7% of gabapentin positive cases had just gabapentin in 
their blood samples, while the remaining 93% of gabapentin positive cases had other 
psychoactive drugs in their sample. Benzodiazepines were found in 44%, opioids in 43%, 
antidepressants in 43%, other CNS depressants in 36%, antiepileptic drugs in 25%, 
cannabinoids in 15%, stimulants in 11% and ethanol in 6% of these polysubstance cases.137 
This indicates that the probability of misusing gabapentinoids is higher when there is opioid 
or polysubstance use. A post-mortem study in West Virginia also found that 77.6% (38 out 
of 49) of cases where gabapentin was a direct cause of death also had at least one opiate 
present in their toxicology report.133 
It is not clear if gender plays a role in increased risk of gabapentinoid misuse and 
abuse, as the distributions of misuse and abuse between males and females have been 
inconsistent across studies.12,26,129 Also, the role of age in gabapentinoid misuse and abuse 
has not been established but abuse-related events have been observed more in younger than 
older participants. 59, 133  
2.4.5.4 Policies and efforts to address gabapentinoid misuse    
In the United Kingdom, both gabapentin and pregabalin were classified as class C 
controlled substances starting on April 1, 2019. This classification will ensure that 
prescribers sign their prescriptions by hand and that they are dispensed within 28 days from 
the prescription date.139 
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However, in the United States, only pregabalin is recognized as a schedule V 
controlled substance while gabapentin remains unclassified as a controlled substance at the 
federal level. This has given rise to various state-level legislations, regulations and 
monitoring efforts to address the increasing evidence of gabapentin misuse.  
Kentucky was the first state (effective July 2017) to classify gabapentin as a 
schedule V controlled substance. This reclassification was established in response to the 
presence of gabapentin in 93 out of 407 (22.9%) cases of overdose-related deaths in 
Jefferson county alone, and in about one-third of all drug related deaths across Kentucky 
in 2016. Schedule V restricts prescribing gabapentin to only prescribers registered with the 
DEA, thereby limiting the ability of mid-level providers to prescribe gabapentin. Also, in 
line with the DEA requirement for schedule III and IV medication refills, no more than a 
6-month supply (i.e., maximum of 5 refills) of gabapentin can be authorized at a time.60, 27, 
28   
West Virginia placed gabapentin on its schedule V controlled drugs list effective 
June 7, 2018 with Tennessee following closely after on July 1, 2018. Michigan and Virginia 
also reclassified gabapentin to a schedule V medication, effective January 2019 and July 
2019, respectively.30, 31, 32 Similarly, North Dakota and Alabama reclassified gabapentin to 
a schedule V medication, effective April 2019 and November 2019, respectively.33, 34 Other 
states such as Minnesota, Ohio, Wyoming, Massachusetts, Nebraska, New Jersey, Kansas 
and New York have included gabapentin in their prescription drug monitoring programs 





Table 2.4: Regulatory action to address gabapentin by various states60,33, 34, 140, 141 
State Action Date 
Kentucky Schedule V reclassification July 1, 2017 
West Virginia Schedule V reclassification June 7, 2018 
Tennessee Schedule V reclassification July 1, 2018 
Michigan Schedule V reclassification January 1, 2019 
North Dakota Schedule V reclassification April 10, 2019 
Virginia Schedule V reclassification July 1, 2019 
Alabama Schedule V reclassification November 18, 2019 
Minnesota PDMP reporting1 August 1, 2016 
Ohio PDMP reporting December 1, 2016 
Wyoming PDMP reporting May 17, 2017 
Massachusetts PDMP reporting August 1, 2017 
Nebraska PDMP reporting January 1, 2018 
New Jersey PDMP reporting May 7, 2018 
Kansas PDMP reporting July 25, 2018 
New York  PDMP reporting January 1, 2019 
1 Prescription drug monitoring programs PDMPs use electronic databases to monitor and report prescription 
information for controlled substances. 
 
2. 5 STUDY SIGNIFICANCE   
The increasing identification of both gabapentin and pregabalin as medications of 
potential misuse and abuse has given rise to public health scrutiny and debate. However, 
limited studies have been conducted to evaluate the prevalence of their misuse alone or 
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concurrently with opioids, as well as their subsequent clinical and economic burden across 
the United States. Evaluating gabapentinoid misuse is important as the opioid epidemic is 
one of the largest health concerns in the country. Gabapentinoids have been considered 
safer alternatives to reduce opioid overuse and subsequent misuse and abuse. However, 
research shows that concurrent use of gabapentinoids with opioids increase the risk of 
overdose and fatalities. 
To the author’s knowledge, only commercial insurance prescription databases in 
the United States have been studied (i.e., the Truven Health MarketScan® and the IBM 
Marketscan® databases). However, Medicaid and Medicare recipients were excluded 
because of the nature of these databases, which precludes information about this patient 
population. Texas is one of the states where, as of 2020, gabapentin has not been 
reclassified or placed on a PDMP. In addition, to date, Texas has not reported data on the 
prevalence of gabapentinoid misuse in the state. Hence, the purpose of this study is to 
evaluate the prevalence and factors associated with gabapentinoid use and misuse using 








Chapter 3:  Methodology 
3.1 CHAPTER OVERVIEW     
Prevalence is the term used to describe the proportion of a specific population 
affected by a disease or condition of interest within a period. It is obtained by comparing 
the affected people to the total number of people studied. It can be expressed as a fraction, 
a percentage or the number of cases per 10,000 or 100,000 people.142  This study examined 
the prevalence of gabapentinoid misuse among Texas Medicaid gabapentinoid users, as 
well as clinical and demographic factors that may be related to misuse. This chapter 
discusses institutional review board approval, study objectives and hypotheses, study 
design and data source, study variables, statistical analytical methods and potential 
limitations.  
 
3.2 INSTITUTIONAL REVIEW BOARD APPROVAL 
This study was reviewed by the Institutional Review Board (IRB) of The University 
of Texas at Austin. It was determined that this project does not require IRB oversight 
because it was conducted with a de-identified data set; hence, there are no direct links to 
patient identifiers. 
 
3.3 STUDY OBJECTIVES AND HYPOTHESES  




2. To describe and compare the demographic characteristics (age and gender) of Texas 
Medicaid gabapentinoid users misusing gabapentinoids versus gabapentinoid users 
not misusing gabapentinoids. 
Ho2a: There is no significant difference in age among gabapentinoid users misusing 
gabapentinoids versus gabapentinoid users not misusing gabapentinoids. 
Ho2b: There is no significant difference in gender among gabapentinoid users 
misusing gabapentinoids versus gabapentinoid users not misusing gabapentinoids. 
 
3. To determine if gabapentinoid misuse differs between gabapentinoid users with and 
without neuropathic pain.  
Ho3:  There is no significant difference in the proportion of patients with 
gabapentinoid misuse among gabapentinoid users with and without neuropathic 
pain.  
 
4. To determine if gabapentinoid misuse differs based on gabapentinoid type. 
H4: The proportion of patients with gabapentinoid misuse is significantly higher in 
gabapentin users compared to pregabalin users.   
 
5. To determine if gabapentinoid misuse differs between concurrent opioid users and 
non-concurrent opioid users. 
H5:  The proportion of patients with gabapentinoid misuse is significantly higher in 
concurrent opioid users compared to non-concurrent opioid users.  
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6. To determine the relationship between likelihood of gabapentinoid misuse by age, 
gender, neuropathic pain diagnosis, gabapentinoid type and concurrent opioid use.   
Ho6a: There is no significant relationship between the likelihood of patients 
misusing gabapentinoids and age, while controlling for covariates.   
Ho6b: There is no significant relationship between the likelihood of patients 
misusing gabapentinoids and gender, while controlling for covariates. 
Ho6c: There is no significant relationship between the likelihood of gabapentinoids 
users misusing gabapentinoid and neuropathic pain diagnosis status, while 
controlling for covariates. 
H6d: Gabapentin users are significantly more likely to misuse gabapentinoids than 
pregabalin users, while controlling for covariates. 
H6e: Concurrent opioid users are significantly more likely to misuse gabapentinoids 
than non-concurrent opioid users, while controlling for covariates.  
 
3.4 STUDY DESIGN AND DATA SOURCE    
This study is a retrospective database analysis using Texas Medicaid prescription 
and medical claims data for the period between January 1, 2012 to August 30, 2016.  The 
study subjects were adults aged 18 to 63 with at least one gabapentinoid (gabapentin or 
pregabalin) prescription.  
 
3.4.1 Inclusion criteria 
Texas Medicaid patients who met the following criteria were included:   
1. Between the ages of 18 and 63 at the index date; 
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2. Continuous enrollment for at least 6 months pre-index and 12 months post-index; 
3. At least one prescription for gabapentin or pregabalin. 
 
3.4.2 Index date 
The index date was the date of the first prescription claim for a gabapentinoid 
(gabapentin or pregabalin) without any previous claims 6 months prior. 
 
3.4.3 Data collection and study periods  
The following data were obtained from the Texas Medicaid eligibility,  medical and 
prescription claims database: de-identified patient identification number, gender, age, 
diagnosis codes (ICD-9-CM and ICD-10-CM codes), prescription medication name and 
type identifiers (i.e., National Drug Codes [NDCs], American Hospital Formulary Service 
[AHFS] code and Generic Code Sequencing Number [GCN_Seq No]), prescription fill 
date, quantity supplied, days’ supply and prescriber type. Data from Texas Medicaid were 
extracted from January 1, 2012 to August 30, 2016. Subjects included in the study were 
identified based on the presence of a prescription claim for a gabapentinoid during the 
index period (July 1, 2012 to August 30, 2015) (Figure 3.1). 
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3.5 STUDY VARIABLES    
This section describes the study variables and operational definition of each 
variable (Table 3.1). 
 
3.5.1 Dependent variable 
The dependent variable in this study was gabapentinoid misuse (Table 3.1). This 
was determined by calculating daily dosage during the 12-month post-index period using 
pharmacy claims. For each claim, total supply dispensed in milligrams was calculated by 
multiplying quantity supplied by strength prescribed. Daily dosage was then calculated 
using total supply dispensed in milligrams divided by days’ supply. Misuse was defined as 
the presence of three or more claims exceeding the daily dose threshold of 3600mg for 
gabapentin and 600mg for pregabalin.  
Total supply = Quantity supplied x strength prescribed 
Daily dose = Total supply dispensed in milligrams / days’ supply 
 January 1, 2012   July 1, 2012       August 30, 2015           August 30, 2016 
   
                 Data extraction period 
   
        Earliest possible  Identification/Index period        Latest possible  
        pre-index period             post-index period 
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3.5.2 Independent variable 
The independent variables included sociodemographic characteristics (age, 
gender), and clinical characteristics (concurrent opioid use, neuropathic pain diagnoses and 
gabapentinoid type). Concurrent opioid use was defined as having a pharmacy claim for at 
least 90 days’ supply of opioid concurrently with a gabapentinoid during the 12-month 
post-index period. Gabapentinoid type was either gabapentin or pregabalin, which was 
assigned based on the index prescription; thus, an intent-to-treat approach was used. See 
Table 3.1 for operational definitions of the independent variables. Neuropathic pain 




Table 3.1: Study variables and operational definitions 
STUDY VARIABLES  OPERATIONAL DEFINITION 
DEPENDENT VARIABLE 
Gabapentinoid misuse 
Three or more claims exceeding daily dose threshold of 3600mg for 
gabapentin or 600mg for pregabalin during the 12-month post-index 
period (see Table 3.3 for brand/generic names of gabapentin and 
pregabalin on the Texas Medicaid formulary). 
[ 0 = no misuse; 1 = misuse] 
INDEPENDENT VARIABLE 
Neuropathic pain diagnosis 
Neuropathic pain diagnoses including postherpetic neuralgia; 
diabetes with neurological manifestations (diabetic neuropathy); 
and others (nerve root and plexus disorders; mononeuritis of upper 
limb and mononeuritis multiplex; mononeuritis of lower limb and 
unspecified site; hereditary and idiopathic peripheral neuropathy; 
inflammatory and toxic neuropathy) identified using ICD-9-CM 
and ICD-10-CM diagnostic codes. (see Table 3.2 for ICD codes) 
[0 = no neuropathic pain present (excluding any of the above);  
 1 = neuropathic pain present (including any of the above)] 
Gabapentinoid type 
Specific type of index gabapentinoid used  
[1 = Gabapentin; 2 = Pregabalin] 
Concurrent opioid use 
Patients with pharmacy claims for at least 90 days’ supply of opioid 
concurrently with a gabapentinoid during the 12-month post-index 
period (see Table 3.3 for brand/generic names of opioids on the 
Texas Medicaid formulary). 
[0 = non-concurrent opioid use; 1 = concurrent opioid use] 
Socio-demographic factors 
Age: Continuous variable, measured as age of subject at index date 
Categorical variable [18-24; 25-40; 41-63] 
Gender: Categorical variable 




Table 3.2: ICD-9-CM and ICD-10-CM diagnostic codes for neuropathic pain143 
 Diagnostic conditions ICD-9-codes ICD-10 codes 
Postherpetic 
neuralgia 
Herpes zoster with unspecified nervous system 
complications 
053.10 B02.29 
Geniculate herpes zoster 053.11 B02.21 
Postherpetic trigeminal neuralgia 053.12 B02.22 
Postherpetic polyneuropathy 053.13 B02.23 
Herpes zoster myelitis 053.14 B02.24 
Herpes zoster with other nervous system 
complications 
053.19 B02.29 






Diabetes with neurological manifestations, type II 
or unspecified type, not stated as uncontrolled 
250.60 E11.40 
Diabetes with neurological manifestations, type I 
[juvenile type], not stated as uncontrolled 
250.61 E10.40  
Diabetes with neurological manifestations, type II 
or unspecified type, uncontrolled 
250.62 E11.40 with 
E11.65 
Diabetes with neurological manifestations, type I 
[juvenile type], uncontrolled 
250.63 E10.40 with 
E10.65 






Atypical facial pain 
350.2 G50.1 
Other disorders of trigeminal nerve 
350.8 G50.8 








Clonic hemifacial spasm 
351.8 G51.31 -G51.39 
Facial myokymia 
351.8 G51.4 
Other disorders of facial nerve 
351.8 G51.8 
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Table 3.2: ICD-9-CM and ICD-10-CM diagnostic codes for neuropathic pain continued 
 
 Disorder of facial nerve, unspecified 
351.9 G51.9 
Disorders of olfactory nerve 
352.0 G52.0 
Disorders of glossopharyngeal nerve 
352.1 or 352.2 G52.1 
Disorders of vagus nerve 
352.3 G52.2 
Disorders of hypoglossal nerve 
352.5 G52.3 
Disorders of multiple cranial nerves 
352.6 G52.7 
Disorders of other specified cranial nerves 
352.4 G52.8 
Cranial nerve disorder, unspecified 
352.9 G52.9 or G53 
Brachial plexus lesions/disorders   
353.0 G54.0 
Lumbosacral plexus lesions/disorders 
  353.1 G54.1 
Cervical root lesions/disorders, not elsewhere 
classified. 353.2 G54.2 
Thoracic root lesions/disorders, not elsewhere 
classified 353.3   G54.3 
Lumbosacral root lesions/disorders, not elsewhere 
classified 353.4 G54.4 
Neuralgic amyotrophy 
353.5 G54.5 
Phantom limb (syndrome) 
353.6 G54.6 or G54.7 
Other nerve root and plexus disorders 
353.8 G54.8 or G55 
Unspecified nerve root and plexus disorder 
353.9 G54.9 
Carpal tunnel Syndrome 
354.0 G56.00- 56.03 
Other lesion of median nerve 
354.1 G56.10-56.13 
Lesion of the ulnar nerve 
354.2 G56.20-56.23 
Lesion of the radial nerve 
354.3 G56.30-56.33 





Table 3.2: ICD-9-CM and ICD-10-CM diagnostic codes for neuropathic pain continued 
 




Mononeuritis of upper limb, unspecified 
354.9 G56.90-56.93 
Lesion of sciatic nerve 
355.0 G57.00-57.03 
Meralgia paresthetica 
355.1 G57.10- 57.13 
Other lesion of femoral nerve 
355.2 G57.20-57.23 
Lesion of lateral popliteal nerve 
355.3 G57.30-57.33 
Lesion of medial popliteal nerve 
355.4 G57.40-57.43 
Tarsal tunnel syndrome 
355.5 G57.50-57.53 
Lesion of plantar nerve 
355.6 G57.60-57.63 
Causalgia of lower limb 
355.71 G57.70-57.73 
Other mononeuritis of lower limb 
355.79 G57.80-57.83 
Mononeuritis of lower limb unspecified 
355.8 G57.90-57.93 
Mononeuritis of unspecified site 
355.9 











Hereditary peripheral neuropathy 
356.0 G60.0 or G60.2 
Peroneal muscular atrophy 
356.1 G60.0 




Idiopathic progressive polyneuropathy 
356.4 G60.3 
Other specified idiopathic peripheral neuropathy 
356.8 G60.8 
Unspecified hereditary and idiopathic peripheral 
neuropathy. 356.9 G60.9 
Acute infective polyneuritis  
 357.0 G61.0 




Table 3.2: ICD-9-CM and ICD-10-CM diagnostic codes for neuropathic pain continued 
 
 
Polyneuropathy in diabetes 
357.2 
E08.42 or E09.42 
or E10.42 or 
E11.42 or E13.42 
Polyneuropathy in malignant disease 
357.3 G63 
Polyneuropathy in other diseases classified 
elsewhere 357.4 
G65.0 or G65.1 or 
G65.2 
Alcoholic polyneuropathy  
 357.5 G62.1 
Polyneuropathy due to drugs  
 357.6 G62.0 
Polyneuropathy due to other toxic agents  
357.7 G61.1 or G62.2 
Chronic inflammatory demyelinating polyneuritis  
357.81 G61.81 
Critical illness polyneuropathy 
 357.82 G62.81 
Other inflammatory and toxic neuropathy  
357.89 
G61.82, G61.89 or 
G64 












Polyneuropathy in other diseases classified 
elsewhere 357.4 G63 
 
Sequelae of Guillain-Barré syndrome 
357.4 G65.0 
 
Sequelae of other inflammatory polyneuropathy 
357.4 G65.1 
 







Table 3.3: Brand/trade names of gabapentinoid and opioid medications on the Texas 
Medicaid formulary144 
Drug Class Generic name Brand/Trade name 
Gabapentinoid Gabapentin Gralise®, Gralise ER®  Horizant 
ER®, Neurontin® 
Pregabalin Lyrica®, Lyrica CR® 
Opioids 
 
Morphine, Morphine ER Embeda ER®, Kadian ER®, 
Morphabond ER®, MS Contin ER® 
Oxycodone, Oxycodone ER, Oxycodone-
Acetaminophen, Oxycodone-Aspirin, Oxycodone-
Ibuprofen, 
Endocet®, Nalocet®, Oxycontin®, 
Percocet®, Roxicodone®, Xtampza 
ER® 
Oxymorphone, Oxymorphone ER Opana® 
Hydrocodone, Hydrocodone-Acetaminophen, 
Hydrocodone-Ibuprofen 
Hysingla ER®, Ibudone®, Lorcet®, 
Norco®, Vicodin® 
Hydromorphone, Hydromorphone ER Exalgo ER®, Dilaudid®, 
Fentanyl Duragesic®, Actiq®, Fentora®, 
Lazanda®, Subsys®    
Methadone Dolophine®, Methadose® 
Meperidine Demerol® 
Buprenorphine, Buprenorphine-Naloxone Belbuca®, Butrans®, Bunavail®, 
Suboxone®, Zubsolv® 
Butorphanol  
Pentazocine, Pentazocine-Naloxone  
Codeine, Acetaminophen-Codeine #2, 
Acetaminophen-Codeine #3, Acetaminophen-
Codeine #4, Butalbital- Caffeine-Acetaminophen-
Codeine, Butalbital- Aspirin-Caffeine-Codeine, 
Carisoprodol-Aspirin-Codeine 
Ascomp with codeine®, Fiorinal-
Codeine®, Tylenol with Codeine 
#3®, Tylenol with Codeine #4® 
Tramadol, Tramadol ER, Tramadol-
Acetaminophen 
Ultracet®, Ultram® 
Tapentadol Nucynta®, Nucynta ER®  
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3.6 STATISTICAL ANALYSIS    
SAS for windows, version 9.4 (SAS Institute, Cary NC) was used for all data 
analyses. All statistical analyses were conducted with two-tailed tests and a significance 
level of p < 0.05. 
Objective 1 was addressed using frequencies. Objective 2 included descriptive and 
inferential analyses. Age was described using mean, standard deviation and range, while 
age categories and gender were described using frequencies. The inferential portion of 
Objective 2 was conducted using an independent samples t-test for the continuous age 
variable, while a chi-square test was conducted for age categories and gender. Chi-square 
tests were also used to analyze Objectives 3, 4 and 5. Objective 6 was analyzed using 
logistic regression. 
 
3.6.1 Statistical test assumptions and sample size calculations 
This section presents the test assumptions and sample size calculations for 
objectives that require statistical tests. A summary of sample size results is shown in Table 
3.4 and a summary of the hypotheses and tests for each objective is included in Table 3.5. 
3.6.1.1 Independent samples t-test 
A t-test was used to test for differences in age (continuous) between the misuse and 
no misuse groups. The assumptions for the t-test include: 1) normal distribution of data; 2) 
homogeneity of variance; and 3) independence of observations.145 The required sample 
size was calculated using G*Power software with medium effect size (d = 0.50), alpha 
level of 0.05 and power of 0.80 for a two-tailed t-test. The minimum required sample size 
for each group was 64, resulting in a total of 128. 
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3.6.1.2 Chi-square test 
Chi-square tests were used to determine if there were differences in proportions 
among categorical variables. For this study, chi-square tests were used to assess differences 
in misuse with respect to: gender (Objective 2); patients with and without a neuropathic 
pain diagnosis (Objective 3); gabapentinoid type (Objective 4); concurrent opioid users 
and non-concurrent opioid users (Objective 5).  
Assumptions required for the Chi-square test include: 1) nominal or categorical 
variables; 2) mutual exclusivity of variables; 3) independence of observations; and 4) at 
least 80% of the cells should contain a minimum expected frequency of 5 observations.146 
Sample size was calculated using G*Power software with medium effect size (f = 0.30), 
alpha level of 0.05 and power of 0.80. The minimum required sample size to use the chi-
square test in this study was 88.  
3.6.1.3 Logistic regression analysis 
Logistic regression analysis was used to address Objective 6 because the dependent 
variable (gabapentinoid misuse) is binary (i.e., yes or no). The following is the logistic 
regression model that was used: 
  
ln [π(x)/(1-π(x))] = β0 + β1x1 + β2x2 + β3x3 + β4x4 + β5x5 
π(x) = probability of misusing gabapentinoids  
1-π(x) = probability of not misusing gabapentinoids 
β0 = constant = intercept of the logistic regression model  
x1 = age  
x2 = gender  
x3 = neuropathic pain diagnosis 
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x4 = gabapentinoid type 
x5 = concurrent opioid use  
 
Using G*Power software, the minimum sample size required was 1,168 (odds ratio 
= 1.2, Pr (Y=1/X=1) H0 = 0.2, α = 0.05, power = 0.8). The logistic regression analysis 
required the largest sample size. Therefore a minimum sample size of 1,168 is necessary 
for this study. 
Table 3.4: Minimum required sample size for each statistical test 




126 88 1,168 
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Table 3.5: Summary of objectives, hypothesis, variables and statistical tests  
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Table 3.5: Summary of objectives, hypothesis, variables and statistical tests continued 
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Table 3.5: Summary of objectives, hypothesis, variables and statistical tests continued 
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Chapter 4: Results 
4.1 CHAPTER OVERVIEW  
This chapter describes the study results. First, the extraction process of patient 
selection from the database will be presented, followed by the results for each study 
objective.   
4.2 FINAL SAMPLE  
The initial population consisted of 149,023 patients with at least one gabapentinoid 
prescription during the study period (July 1, 2012 – August 30, 2015). After applying all 
inclusion and exclusion criteria, there were 39,000 eligible patients for the final sample 
(Table 4.1).  
Table 4.1: Attrition of study subjects  
Criteria Subjects excluded Subjects remaining 
N % N % 
Initial population (patients with at 
least one gabapentinoid prescription 
between July 1, 2012 and August 30, 
2015 
  149,023 100 
Excluded if had index date prior to 
July 1, 2012 or after August 30, 
2015 
62,732 42.1 86,291 57.9 
Sample after prior stage   86,291 100 
Included age 18 to 63 at index date 7,487 8.7 78,804 91.3 
Sample after prior stage   78,804 100 
Included if continuous enrollment 
(patients with claims for at least 6 
quarters during the study period) 
39,804 50.5 39,000 49.5 
Final sample (total patients 
excluded or remaining from initial 
sample) 
110,023 73.8 39,000 26.2 
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4.3 STUDY OBJECTIVES 
4.3.1 Objective 1: To quantify the proportion of Texas Medicaid gabapentinoid 
users with gabapentinoid misuse.  
 Objective 1 was to quantify the proportion of Texas Medicaid gabapentinoid users 
with gabapentinoid misuse. There were N = 81 (0.2%) gabapentinoid users who met the 
criteria for gabapentinoid misuse (Table 4.2).  
Table 4.2: Proportion of gabapentinoid users with gabapentinoid misuse (N=39,000) 
 N % 
Misuse 81 0.2 
No misuse 38,919                   99.8 
Total 39,000 100.0 
 
4.3.2 Objective 2: To describe and compare the demographic characteristics (age 
and gender) of Texas Medicaid gabapentinoid users misusing gabapentinoids versus 
gabapentinoid users not misusing gabapentinoids. 
Objective 2 was to compare the demographic (age and gender) characteristics of 
gabapentinoid misusers with non-misusers (Table 4.3). Note that race/ethnicity was 
omitted due to missing values. Overall, the majority of gabapentinoid users were 41 to 63 
years of age (76.4%) with a mean±SD age of 48.2±10.7 years and they were predominantly 
female (68.1%).  
When comparing gabapentinoid misusers to non-misusers, a t-test revealed that 
gabapentinoid misusers were significantly younger than gabapentinoid non-misusers 
(45.1±11.0 vs. 48.2±10.7, respectively; p = 0.0084). Among the age groups, a chi-square 
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test revealed that there was no significant difference in the proportion of misusers across 
three age group categories, 18-24, 25-40, and 41-63, respectively (X2 = 4.2, p =0.1219). 
Therefore, the hypothesis below was rejected. Note that although both t-test and chi-square 
tests were run for age, the t-test was associated with the hypothesis below. 
Ho2a: There is no significant difference in age among gabapentinoid users misusing 
gabapentinoids versus gabapentinoid users not misusing gabapentinoids. Rejected 
With respect to gender, a chi-square test revealed that a significantly (X2 = 7.0, p = 
0.0079) higher proportion of males (0.3%) misused gabapentinoids compared to females 
(0.2%). Therefore, the hypothesis below was rejected. 
Ho2b: There is no significant difference in gender among gabapentinoid users 
misusing gabapentinoids versus gabapentinoid users not misusing gabapentinoids. 
Rejected 
Table 4.3: T-test and chi-square comparison of demographic characteristics of 




N (col %) 
Misuse  
N (row %) 
No misuse  
N (row %) 
p-value 
Age  
Mean (±SD) 48.2 (±10.7) 45.1 (±11.0) 48.2 (±10.7) 0.0084a 
Age groups, N (%) 
18-24 1,126 (2.9%) 5 (0.4%) 1,121 (99.6%) 0.1219b 
25-40 8,083 (20.7%) 20 (0.3%) 8,063 (99.7%) 
41-63 29,791 (76.4%) 56 (0.2%) 29,735 (99.8%) 





4.3: T-test and chi-square comparison of demographic characteristics of gabapentinoid 
users (N = 39,000) continued 
Gender, N (%) 
Females 26,543 (68.1%) 44 (0.2%) 26,499 (99.8%) 0.0079b 
Males 12,457 (31.9%) 37 (0.3%) 12,420 (99.7%) 





4.3.3 Objective 3: To determine if gabapentinoid misuse differs between 
gabapentinoid users with and without neuropathic pain. 
Objective 3 was to determine if gabapentinoid misuse differs between 
gabapentinoid users with and without neuropathic pain (Table 4.4). Overall, slightly over 
one-half (51.9%; N=20,247) of the subjects had a neuropathic pain diagnosis. 
A chi-square test revealed that gabapentinoid misuse was significantly (X2 = 7.0, p 
= 0.0078) higher among gabapentinoid users with neuropathic pain (0.3%) compared to 
gabapentinoid users without neuropathic pain (0.1%). Therefore, the hypothesis below was 
rejected. 
Ho3:  There is no significant difference in the proportion of patients with 







Table 4.4: Chi-square comparison of gabapentinoid misuse between users with and 
without neuropathic pain (N = 39,000) 
Diagnosis All users  
N (col %) 
Misuse   
N (row %) 
No misuse  
N (row %) p-value 
Neuropathic pain 20,247 (51.9%) 54 (0.3%) 20,193 (99.7%) 0.0078a 
No neuropathic pain 18,753 (48.1%) 27 (0.1%) 18,726 (99.9%) 
Total 39,000 (100.0%) 81 (0.2%) 38,919 (99.8%) 
a Chi-square test 
 
4.3.4 Objective 4: To determine if gabapentinoid misuse differs based on 
gabapentinoid type. 
Objective 4 was to determine if gabapentinoid misuse differed based on 
gabapentinoid type (Table 4.5). Overall, there were N = 30,177 (77.4%) gabapentin users 
and N = 8,823 (22.6%) pregabalin users.  
 A chi-square test revealed that gabapentinoid misuse was significantly (X2 = 13.2, 
p = 0.0003) higher among pregabalin users (0.4%) than gabapentin users (0.2%). 
Therefore, the hypothesis below was rejected.  
H4: The proportion of patients with gabapentinoid misuse is significantly higher in 
gabapentin users compared to pregabalin users. Rejected 
Table 4.5: Chi-square comparison of gabapentinoid misuse among gabapentin users vs 
pregabalin users (N = 39,000) 
Gabapentinoid 
type 
All users  
N (col %) 
Misuse  
N (row %) 
No misuse  
N (row %) 
p-value 
Gabapentin 30,177 (77.4%)  49 (0.2%) 30,128 (99.8 %) 0.0003a 
Pregabalin 8,823 (22.6%)  32 (0.4%) 8,791 (99.6%) 
Total 39,000 (100.0%) 81 (0.2%) 38,919 (99.8%) 
a Chi-square test 
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4.3.5 Objective 5: To determine if gabapentinoid misuse differs between concurrent 
opioid users and non-concurrent opioid users. 
Objective 5 was to determine if gabapentinoid misuse differed between concurrent 
opioid users and non-concurrent opioid users (Table 4.6). Overall, there were 6,755 
(17.3%) gabapentinoid users with at least 90-day concurrent opioid use.  
A chi-square test revealed that there was no significant (X2 = 2.1, p = 0.1440) 
difference in gabapentinoid misuse among gabapentinoid users with 90-day concurrent 
opioid use (0.3%) compared to gabapentinoid users without 90-day concurrent opioid use 
(0.2%). Therefore, the hypothesis below was rejected. 
H5:  The proportion of patients with gabapentinoid misuse is significantly higher 
in concurrent opioid users compared to non-concurrent opioid users. Rejected 
A sensitivity analysis revealed that there was no significant (X2 = 3.4, p = 0.0660) 
difference in gabapentinoid misuse among gabapentinoid users with at least 60-day 
concurrent opioid use (0.3%) compared to gabapentinoid users without 60-day concurrent 
opioid use (0.2%).  Similarly, there was no significant (X2 = 3.1, p = 0.798) difference in 
gabapentinoid misuse among gabapentinoid users with at least 120-day concurrent opioid 
use (0.3%) compared to gabapentinoid users without 120-day concurrent opioid use 
(0.2%). 
Table 4.6: Chi-square comparison of gabapentinoid misuse among 90-day concurrent 
opioid users compared to non-concurrent opioid users (N = 39,000) 
Concurrent opioid user 
status 
All users  
N (col %) 
Misuse  
N (row %) 
No misuse  
N (row %) 
p-value 
Concurrent opioid users 6,755 (17.3%) 19 (0.3%) 6736 (99.7%) 0.1440a 
Non-concurrent opioid users 32,245 (82.7%) 62 (0.2%) 32183 (99.8%) 
Total 39,000 (100.0%) 81 (0.2%) 38,919 (99.8%) 
a Chi-square test 
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4.3.6 Objective 6: To determine the relationships between likelihood of 
gabapentinoid misuse and age, gender, neuropathic pain diagnosis, gabapentinoid 
type and concurrent opioid use.   
Objective 6 was to determine the likelihood of gabapentinoid misuse by age, 
gender, neuropathic pain diagnosis, gabapentinoid type and concurrent opioid use. A 
logistic regression test revealed that the likelihood of gabapentinoid misuse was 
significantly associated with age, gender, neuropathic pain diagnosis and gabapentinoid 
type (Table 4.7). 
For every year increase in age, the odds of misusing gabapentinoids decreased by 
3.3% (OR = 0.967, 95% CI = 0.949-0.986; p = 0.0007). Therefore, the hypothesis below 
was rejected. 
Ho6a: There is no significant relationship between the likelihood of patients 
misusing gabapentinoids and age, while controlling for covariates. Rejected  
The odds of misusing gabapentinoids were 51.4% lower for females compared to 
males. (OR = 0.486, 95% CI = 0.313-0.756; p = 0.0013).  Therefore, the hypothesis below 
was rejected.  
Ho6b: There is no significant relationship between the likelihood of patients 
misusing gabapentinoids and gender, while controlling for covariates. Rejected 
The odds of misusing gabapentinoids were 2.1 times higher for gabapentinoid users 
with neuropathic pain diagnosis compared to gabapentinoid users without neuropathic pain 
diagnosis. (OR = 2.065, 95% CI = 1.289-3.308; p = 0.0026). Therefore, the hypothesis 
below was rejected.  
Ho6c: There is no significant relationship between the likelihood of gabapentinoid 
users misusing gabapentinoids and neuropathic pain diagnosis status, while controlling 
for covariates. Rejected   
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The odds of misusing gabapentinoids were 2.3 times higher for pregabalin users 
compared to gabapentin users. (OR = 2.337, 95% CI = 1.492-3.661; p = 0.0002). Therefore, 
the hypothesis below was rejected.  
H6d: Gabapentin users are significantly more likely to misuse gabapentinoids than 
pregabalin users, while controlling for covariates. Rejected 
The likelihood of misusing gabapentinoids was not significantly associated with 
concurrent opioid use. (OR = 1.542, 95% CI = 0.920-2.586; p = 0.1006). Therefore, the 
hypothesis below was rejected. 
H6e: Concurrent opioid users are significantly more likely to misuse gabapentinoids than 
non-concurrent opioid users, while controlling for covariates. Rejected 
 
Table 4.7: Logistic regression analysis of gabapentinoid misuse by age, gender, 
neuropathic pain diagnosis and gabapentinoid type (N = 39,000) 
Independent variable Odds ratio 95% CI Wald X2 p-value 
Age 0.967 0.949-0.986 11.62 0.0007 
Gender: Female 0.486 0.313-0.756 10.27 0.0013 
Neuropathic pain diagnosis 2.065 1.289-3.308 9.10 0.0026 
Gabapentinoid type: 
Pregabalin 
2.337 1.492-3.661 13.75 0.0002 
Concurrent opioid use 1.542 0.920-2.586 2.70 0.1006 





Table 4.8: Summary of hypotheses testing 
Objectives/Hypotheses Result 
Objective 1: To describe the proportion of Texas Medicaid gabapentinoid users with gabapentinoid 
misuse. 
Objective 2: To describe and compare the demographic characteristics (age and gender) of Texas 
Medicaid gabapentinoid users misusing gabapentinoids versus gabapentinoid users not misusing 
gabapentinoids. 
Ho2a: There is no significant difference in age among 
gabapentinoid users misusing gabapentinoids versus 
gabapentinoid users not misusing gabapentinoids.  
Rejected 
Misusers were significantly younger than 
non-misusers. 
Ho2b: There is no significant difference in gender among 
gabapentinoid users misusing gabapentinoids versus 
gabapentinoid users not misusing gabapentinoids.  
Rejected 
A higher proportion of males misused 
gabapentinoids compared to females. 
Objective 3: To determine if gabapentinoid misuse differs between gabapentinoid users with and 
without neuropathic pain. 
Ho3: There is no significant difference in gabapentinoid 
misuse between gabapentinoid users with and without 
neuropathic pain.  
Rejected 
Misuse was higher among users with 
neuropathic pain compared to users without 
neuropathic pain. 
Objective 4: To determine if gabapentinoid misuse differs based on gabapentinoid type. 
H4: Gabapentinoid misuse is significantly higher in 
gabapentin users compared to pregabalin users 
Rejected 
The rate of misuse in pregabalin users was 
higher than misuse in gabapentin users 
Objective 5: To determine if gabapentinoid misuse differs between concurrent opioid users and 
non-concurrent opioid users. 
H5: Gabapentinoid misuse is significantly higher in 
concurrent opioid users compared to non-concurrent 
opioid users.  
Rejected 
There was no significant difference in misuse 
in concurrent opioid users compared to non-
concurrent opioid users. 
Objective 6: To determine the relationships between likelihood of gabapentinoid misuse by age, 
gender, neuropathic pain diagnosis, gabapentinoid type and concurrent opioid use.   
Ho6a: There is no significant relationship between the 
likelihood of patients misusing gabapentinoids and age, 
while controlling for covariates. 
Rejected 
For every year increase in age, the odds of 




Table 4.8: Summary of hypotheses testing continued 
 
Ho6b: There is no significant relationship between the 
likelihood of patients misusing gabapentinoids and 
gender, while controlling for covariates. 
Rejected 
The odds of misusing gabapentinoids were 
51.4% lower for females compared to males. 
Ho6c: There is no significant relationship between the 
likelihood of gabapentinoid users misusing 
gabapentinoids and neuropathic pain diagnosis status, 
while controlling for covariates. 
Rejected 
The odds of misusing gabapentinoids were 
2.1 times higher for gabapentinoid users 
with neuropathic pain diagnosis compared to 
gabapentinoid users without neuropathic 
pain diagnosis. 
H6d: Gabapentin users are significantly more likely to 
misuse gabapentinoids than pregabalin users, while 
controlling for covariates.  
Rejected 
The odds of misusing gabapentinoids were 
2.3 times higher for pregabalin users 
compared to gabapentin users. 
H6e: Concurrent opioid users are significantly more likely 
to misuse gabapentinoids than non-concurrent opioid 
users, while controlling for covariates.  
Rejected 
The likelihood of misusing gabapentinoids 
was not significantly associated with 












Chapter 5:  Discussion and Conclusions 
5.1 CHAPTER OVERVIEW 
This chapter contains the discussion of the study results and it is divided into four 
sections. The first section covers a discussion of study results in light of the current 
literature. The second section discusses the study limitations, the third section cover 
suggestions for future research while the final section includes the study conclusions. 
 
5.2 DISCUSSION OF STUDY FINDINGS 
5.2.1 Objective 1 
The purpose of objective 1 was to quantify the proportion of Texas Medicaid 
gabapentinoid users with gabapentinoid misuse. Only 0.2% of the study population met the 
criteria for gabapentinoid misuse. While studies exist regarding gabapentinoid use and 
misuse, there are limited retrospective database studies that focus on prevalence of 
gabapentinoid misuse. One such study, by Peckham et.al., used the Truven Health 
MarketScan® commercial database where they defined misuse as having three or more 
pharmacy claims that exceeded the recommended daily threshold. This definition is similar 
to our definition of misuse, however, the prevalence of gabapentinoid misuse in their study 
was higher than ours (2.7%).61 The authors indicated (personal communication) that the 
database captured all prescription transactions including cash payments. The database also 
included multiple claims from different prescribers and filled at multiple pharmacies. Thus, 
their study potentially captured doctor and pharmacy shopping and patients getting 
prescriptions from multiple sources. Whereas in our study, Medicaid policies may preclude 
patients from obtaining: early prescription refills, multiple prescriptions for the same 
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medication, or prescriptions that consistently exceed FDA approved doses.147, 148 Thus, a 
contributor to the difference in our study results and those using the Truven database may 
be stricter Medicaid policies, as well as the inability to capture cash paying prescriptions 
in the Medicaid database. Also, misuse may be underestimated in any study if patients 
obtain these medications outside of the healthcare network. Studies have shown that a 
significant percentage of access to gabapentinoids, specifically gabapentin, may be outside 
of legitimate doctor/pharmacy relationships.60, 118, 131, 132 A qualitative study conducted in 
Kentucky found that about 36% of access to gabapentin could be attributed to illegal drug 
purchases.131, 132 Finally, it is also possible that gabapentinoid misuse is not prevalent 
among Texas Medicaid recipients. It is unclear if the prevalence of gabapentinoid misuse 
differs among various patient populations.   
 
5.2.2 Objective 2 
Objective 2 was to describe and compare the age and gender of Texas Medicaid 
gabapentinoid users misusing gabapentinoids versus gabapentinoid users not misusing 
gabapentinoids. In this study, the mean (±SD) age of subjects was 48.2 (±10.7). The mean 
(±SD) age of non-misusers was the same as the overall mean age of all subjects. However, 
the mean (±SD) age of misusers was 45.1 (±11.0), and this was significantly lower than 
non-misusers. The mean age of subjects in this study was only slightly lower than the 
participants in the Truven study, as gabapentin and pregabalin users had a mean (±SD) age 
of 50 (±11.0) and 49 (±9.0), respectively.25 In the FAERS study by Evoy et. al., the mean 
(±SD) age for all patients with gabapentin adverse events was 56.2 (±15.6). However, the 
mean age was lower [46.6 (±17.1)] for abuse-related events. Similarly, for pregabalin, the 
overall mean (±SD) age for adverse events was 48.9 (±16.3) but for abuse-related events, 
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the mean (±SD) age was lower [36.1 (± 12.7)].59 A study conducted in Sweden found that 
pregabalin misuse was associated with younger (18 to 29 years old) rather than older (≥ 65 
years old) adults.149 The role of age in gabapentinoid misuse is not clear but studies have 
found an association with younger age and gabapentinoid misuse/abuse.25, 59, 126 While our 
study supported this trend, it is important to note that the difference in age between users 
and misusers (~3 years) may not be practically significant. 
With respect to gender, there was a higher proportion of females (68.1%) than 
males in the study sample. However, there was a significantly higher proportion of misuse 
among males (0.3%) compared to females (0.2%). The results regarding gender cannot be 
compared to other studies as the distributions of misuse between females and males have 
been inconsistent across studies.12, 26, 129 Note that although statistically significant, the 
difference was minimal and not likely practically significant. 
 
5.2.3 Objective 3 
Objective 3 was to determine if gabapentinoid misuse differs between 
gabapentinoid users with and without neuropathic pain. Among other conditions, 
gabapentin and pregabalin are both indicated for the management of neuropathic pain.8, 14 
Gabapentin and pregabalin have demonstrated effective neuropathic pain management in 
different studies.9, 150 About 52% (N = 20,247) of our study sample had a neuropathic pain 
diagnosis. The number of gabapentinoid misusers with neuropathic pain diagnoses was two 
times higher than those without (N = 54 vs. N=27, respectively). A chi-square test revealed 
that gabapentinoid misuse was significantly higher in patients with neuropathic pain 
diagnosis (0.3%) compared to patients without neuropathic pain diagnosis (0.1%). 
Although the differences in proportion (0.3% vs 0.1%) may be considered minimal similar 
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to results regardin gender, the size of the groups being compared in this objective is almost 
equal (52% vs 48%) making the differences in proportion practically meaningful. 
Currently, there is a paucity of research comparing gabapentinoid misuse 
specifically in patients with and without neuropathic pain diagnosis. The results of our 
study may indicate gabapentinoid misuse may not always be the result of irresponsible use 
but possibly due to the need for higher pain management in patients with neuropathic pain. 
This consideration is especially important in quantitative studies where factors such as pain 
level may not be easily extrapolated from medical and prescription claims data. 
 
5.2.4 Objective 4  
Objective 4 was to determine if gabapentinoid misuse differs based on 
gabapentinoid type. The gabapentinoids evaluated in this study were pregabalin and 
gabapentin. Pregabalin was first approved in 2004 for the treatment of diabetic peripheral 
neuropathy and postherpetic neuralgia.11, 12 Gabapentin was first approved in 1993 as an 
adjunct treatment for partial complex seizures in people over 12 years old. This approval 
was later extended to include treatment for postherpetic neuralgia in 2002.113 Pregabalin 
was classified as a schedule V controlled substance by the DEA at the time of its release, 
while gabapentin is not classified as a controlled substance federally because it was 
believed to have a low potential for abuse.13 However, with evidence showing exponential 
increases in gabapentin prescribing and its presence in overdose and autopsy reports, 
concerns about the potential for misuse and abuse with gabapentin is increasing.14, 15, 26, 35, 
59, 133 About 26 years after gabapentin was first approved, the FDA is now requiring 
manufacturers to conduct clinical trials evaluating the abuse potential of gabapentinoids.135, 
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136 Currently, 7 states have made gabapentin a schedule V controlled substance and at least 
8 other states require monitoring of gabapentin prescribing and dispensing.60,33, 34, 140, 141 
The goal of this objective was to determine if gabapentinoid misuse differs based 
on gabapentinoid type. In this study, 77.4% (N = 30,177) of the sample were gabapentin 
users, while 22.6% (N= 8,823) were pregabalin users and a chi-square analysis revealed 
that the proportion of misuse among pregabalin users (0.4%) was significantly higher than 
gabapentin users (0.2%). This was different from our hypothesis, as we expected the 
proportion of misuse among gabapentin users to be higher than among pregabalin users. 
We had this expectation because unlike pregabalin, gabapentin is not controlled at the 
federal level. Also, some studies show increasing evidence of gabapentin prescribing and 
misuse.14, 15, 35, 59 However, other studies have shown higher proportion of misuse among 
pregabalin users compared to gabapentin users.59, 129    
In the Eudravigilance pharmacovigilance study, 6.6% of pregabalin adverse events 
reports were attributed to misuse, abuse and dependence while 4.8% of gabapentin adverse 
events reports were attributed to misuse, abuse and dependence.129 The pattern in our study 
may be comparable to the pattern observed in the FAERS study by Evoy et. al.59 In their 
study, a substantially higher number of gabapentin adverse events (N = 10,038) were 
identified compared to pregabalin (N = 571). However, the proportion of these reports 
related specifically to abuse was higher in pregabalin (10%) than gabapentin (5.7%). While 
evidence shows that gabapentin prescribing and misuse is increasing, 14, 15, 35, 59 the 
gabapentinoid with a higher proportion of misuse in our study population was pregabalin. 
Similar to other studies, our study shows that gabapentinoid misuse differs based on 
gabapentinoid type and is significantly higher among pregabalin users than gabapentin 
users in this population. 
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5.2.5 Objective 5  
Objective 5 was to determine if gabapentinoid misuse differs between concurrent 
opioid users and non-concurrent opioid users. The concern about gabapentinoid misuse 
significantly increases when there is concurrent opioid use. Some studies suggest that 
overdose of gabapentinoids alone may not have lethal effects but when used in combination 
with opioids or sedatives, side effects of opioid overuse such as respiratory depression can 
increase up to 60%. 60, 118, 126, 138  
In this study, about 57% (N = 22,102) of patients used opioids concurrently for at 
least one day. This is comparable to what was observed in the IBM Marketscan® database 
study by Pauly et. al. They found that about 61% of people who have been prescribed 
gabapentin had at least one opioid prescription.35 Similarly, a case control study in Canada 
found that about 46% of gabapentin users had at least one concurrent opioid prescription, 
and this concurrent use increased opioid-related fatality by 49%. 107 
Further analysis of our data revealed that 23% (N = 9,147), 17% (6,755) and 13% 
(5,139) of gabapentinoid users had concurrent opioid use for at least 60, 90 and 120 days, 
respectively. Based on previous studies, we expected the proportion of concurrent opioid 
users to be higher. Also, there was no significant difference in gabapentinoid misuse among 
concurrent opioid users for at least 90 days (0.3%) compared to non-concurrent opioid 
users for at least 90 days (0.2%). A sensitivity analysis was performed to determine how 
misuse differed among concurrent opioid users for at least 60 days and 120 days. However, 
results of the sensitivity analysis showed that there was no significant difference in misuse 
among both the 60-day and 90-day concurrent opioid users and non-concurrent opioid 
users.  
These results were unexpected because previous studies suggest that opioid use is 
a risk factor for gabapentinoid misuse. Gabapentinoids have been found to potentiate the 
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“high” obtained from opioid use which can lead to increased gabapentinoid misuse in 
concurrent opioid users.126, 130, 131, 132 In the Truven® database study by Peckham et. al., the 
authors found that about 22% of gabapentin users and 26% of pregabalin users had 
concurrent opioid use for at least 120 days within a 12-month period. 25 They also found 
that 24% of patients who had both gabapentin and opioid prescriptions, and 28% of patients 
who had both pregabalin and opioid prescriptions had no less than three pharmacy claims 
that exceeded recommended dosage limits, in contrast to 3% of patients on gabapentin 
alone, 5% of patients on pregabalin alone and 8% of patients on opioids alone.25  
In another study where the authors categorized gabapentin overuse into mild and 
sustained, they found that only 2% of patients on gabapentin alone met their prolonged 
overuse criteria but 11% of patients on both gabapentin and opioids met the prolonged 
overuse criteria. Prolonged overuse was defined as exceeding dosage threshold for three or 
more “rolling” calendar quarters. While their definition for overuse/misuse in this study 
was different from ours, they found that there were more concomitant opioid users who 
met the prolonged overuse criteria compared to those who did not use opioid 
concomitantly.111  
 
5.2.6 Objective 6 
The goal of Objective 6 was to determine the likelihood of gabapentinoid misuse 
by age, gender, neuropathic pain diagnosis, gabapentinoid type and concurrent opioid use, 
while controlling for remaining covariates. The results of the logistic regression were 
consistent with the observations in our bivariate analysis for the above objectives.  
We observed that, the likelihood of gabapentinoid misuse decreases with an 
increase in age; females were less likely to misuse gabapentinoids compared to males; 
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patients with neuropathic pain diagnosis were twice as likely to misuse gabapentinoids 
compared to patients without neuropathic pain diagnosis; pregabalin users were also twice 
as likely to misuse gabapentinoids compared to gabapentin users; and finally, the likelihood 
of misusing gabapentinoids was not significantly associated with concurrent opioid use.  
 
5.3 IMPLICATION OF FINDINGS  
Our findings suggest that Texas Medicaid has policies in place that limit the misuse 
of gabapentinoids. However, there is still some amount of misuse that can be further 
evaluated. For clinicians, this study sheds light on the possibility and presence of 
gabapentinoid misuse. While this may not be considered a pressing problem among Texas 
Medicaid recipients, an understanding of gabapentinoid misuse and potential related 
suboptimal outcomes would be informative for clinicians.  For Texas Medicaid recipients, 
this study creates awareness regarding the potential for misusing gabapentinoids. 
Awareness on the possibility of misuse and consequences would be beneficial for this 
group. 
 
5.4 STUDY LIMITATIONS  
The purpose of this study was to assess the prevalence and factors associated with 
gabapentinoid use and misuse among Texas Medicaid recipients. Some limitations that 
may affect the study results are discussed below. First, the risk of error associated with 
retrospective database studies may impact our results. This study depended on the accuracy 
of prescription days’ supply to define misuse and diagnosis codes to determine indications 
for neuropathic pain. The possibility for entry or misclassification errors can lead to 
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exclusion or improper classification.  Second, patients were evaluated based on either 
gabapentin or pregabalin misuse, thus omitting those who may have used both gabapentin 
and pregabalin (N~7,700 in the present study) There is a possibility that patients who may 
not have met the criteria for misuse based on only one medication, may have been classified 
as misusers if dual therapy were considered. Thus, the prevalence of misuse may have been 
underestimated. Third, we may not have captured the total medication use of patients 
within the study period as gabapentinoids can be accessed outside legitimate 
doctor/pharmacist network. This information is not usually captured in claims data. Also, 
other relevant factors related to medication use or misuse such as pain level, tobacco and 
alcohol use, and previous incarceration may not be easily obtained from claims and 
diagnosis data, but may be important in assessing reasons or predictors of misuse. Finally, 
the study was limited to only Texas Medicaid recipients and may not be generalizable to a 
different socio-economic or demographic groups nor other state Medicaid programs. 
 
5.5 SUGGESTIONS FOR FUTURE RESEARCH  
The main purpose of this study was to examine the prevalence of and factors 
associated with gabapentinoid use and misuse among Texas Medicaid recipients. This 
study utilized a retrospective database analysis to achieve this purpose. However, a 
limitation of this method is that gabapentinoids accessed outside the legitimate 
doctor/pharmacist network was not captured. Future qualitative studies may shed light on 
the possibility of gabapentinoid use and misuse outside this network.  
Gabapentinoid misuse research is an emerging area, and as such, gaps of knowledge 
exist in the literature. It is not yet clear the role age, gender or socioeconomic status plays 
in gabapentinoid misuse. In the Pauly et al., study, the authors observed disparities in 
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gabapentin prescribing across different states with Kentucky and Washington DC., having 
the highest (43.9 per 1000 beneficiaries) and lowest (12.7 per 1000 beneficiaries) 
prescribing rates, respectively.35 It is not clear why these disparities occur across different 
states. Further research into the role of demographic and environmental characteristics can 
provide useful information for intervention strategies. 
Also, the discovery of significantly higher misuse among patients with a 




Studies have shown an increase in the utilization rates of gabapentin and pregabalin 
within the last few years. Also, the potential for misuse and abuse of gabapentinoids have 
become a public health concern. As a result, several states have adopted some type of 
mechanism to monitor and control gabapentinoid prescribing.  
Our study showed that the prevalence of gabapentinoid misuse was low among 
Texas Medicaid recipients, as only 0.2% misused gabapentinoids. We discovered that 
gabapentinoid misuse was more prevalent among younger adults, males, patients with 
neuropathic pain diagnosis and pregabalin users. Unexpectedly, gabapentinoid misuse was 
not significantly associated with concurrent opioid use. However, our study results are 
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